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1 .  I N T R O D U C T I O N  
 
 
Stroke-related brain injury is a major cause of mortality and severe neurological disability. 
In practice, stroke refers to a range of conditions that are caused by occlusion or 
hemorrhage of one of the main arteries supplying blood to cerebral tissues. Ischemia is 
simply defined as the diminution of cerebral blood flow (CBF) to a critical threshold that 
propagates brain damage. Focal cerebral ischemia entails reduction in CBF to a specific 
vascular territory, usually encountered clinically due to thrombotic, embolic or 
hemorrhagic strokes [1]. The tissue in the center of the ischemic area with severe CBF 
reduction, is termed as ischemic core. Distal from the ischemic core towards the regions 
where the blood flow is normal, the ischemic injury becomes progressively less severe. 
This peripheral region of the ischemic territory in which the blood flow reduction is less 
severe, corresponds to the so-called ischemic penumbra. The relative maintenance of 
perfusion in the ischemic penumbra is the result of collateral blood flow operating from the 
adjacent non-ischemic territory (for review, see [2]). The majority of strokes are a result of 
focal ischemia and one of the major blood vessels affected is the middle cerebral artery 
(MCA) [3]. Another cause, global cerebral ischemia, involves a reduction or absence of 
CBF to the entire brain, situations usually encountered in severe hypotension or acute 
cardiac arrest [1]. In all cases, the stroke ultimately involves dysfunction or death of brain 
cells, giving rise to cerebral infraction. Depending on the location and size of the infarct, 
stroke may lead to neurological deficits or in severe cases, death of the subject.  
The primary event during ischemia is the inhibition of the electron transport chain and 
hence, oxidative phosphorylation because of reduced supply of oxygen and glucose to the 
affected tissue. This fall in respiration is followed by a rapid decrease in adenosine 
triphosphate (ATP) levels [4]. Consequently ATP-dependent elements, such as the Na+ 
pump is inhibited, causing an imbalance in Na+ / K+ ion concentrations and a membrane 
depolarization in the cells of affected cerebral tissue [5]. These changes are very dramatic 
during global ischemia and also in the core of focal lesions. However, such changes are 
much less severe in the penumbra of focal lesions [6]. In the penumbra, the levels of ATP 
do not fall nearly as much as in global ischemia or the core. All these events initiate the 
pathways of cell death in stroke.  
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1.1 Cell death in cerebral ischemia 
 
 
The characterization of the cell death pathways in stroke is of primary importance to 
develop therapeutic interventions. Cell death in ischemia has traditionally been considered 
as “necrotic”. During the last decade, research has revealed that apoptosis equally 
contributes to the ischemic cell death [7-9]. Apoptosis is an energy dependent pathway that 
involves an active proteolytic process, which leads to nuclear and cytoplasmic 
condensation, intra-nucleosomal DNA fragmentation and cell compartmentalization into 
apoptotic bodies that are engulfed by neighboring macrophages [10, 11] The phagocytic 
action of macrophages rapidly remove the apoptotic cells, without eliciting an 
inflammatory reaction. In contrast, necrosis results from energy depletion, dissipation of 
ionic gradients, cell swelling, disruption and permeabilisation of the plasma membrane and 
loss of intracellular contents, leading to inflammatory response [12].  
In ischemia, the involvement of apoptotic cell death is now widely accepted, however, 
questions arise from the fact that the morphological features of ischemic cell death do not 
correlate with the molecular markers of apoptosis. Two main hypothesis have been 
proposed to reconcile the biochemical and morphological evidences of ischemic cell death. 
The first is that ischemic cell death may proceed via a number of pathways with similar 
operative mechanisms, which lead to apoptosis as well as necrosis [13, 14]. Such common 
mechanisms include excitatory amino acid release and ionic imbalance that contribute to 
both apoptosis and necrosis. An alternative hypothesis is based on the concept that 
apoptosis may be masked by necrosis under ischemic conditions [15, 16]. In-vitro studies 
have provided examples of shifts from apoptosis to necrosis and vice versa [17-19]. In 
ischemic tissue, the energy levels in the infarct core approach zero [20] but respiration is  
maintained, at least partially, in the penumbra by collateral reperfusion from adjacent 
arteries, providing a suitable environment for neuronal apoptosis to fully occur. Although 
many morphological and biochemical observations of the ischemic cells have been made 
during the late stages of infarction [12], the neurons of the so called necrotic core display 
features of apoptosis [12]. Caspase activation, apoptotic DNA fragmentation and dilation 
of endoplasmic reticulum (ER) have been observed in cerebral infarctions [12, 21, 22]. 
Thus, apoptosis is indeed being triggered by ischemia but as the availability of the cellular 
energy declines, apoptotic degenerative processes are replaced by necrotic processes [12] 
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In ischemic tissue, electron microscopic studies revealed mixed markers for both apoptosis 
and necrosis within the same cell [23]. These studies indicate that there is a co-existence of 
apoptosis and necrosis in ischemic tissue. The main stream executors of apoptosis are 
Caspases that consist of a family of proteases which possess a cysteine-containing 
pentapeptide catalytic site and require an aspartate residue at the N-terminal end of the 
substrate cleavage site. Caspases are synthesized as inactive proenzymes (procaspases) that 
comprise an N-terminal prodomain, a large and a small subunit. Activation results from 
proteolytic cleavage of the procaspase into its three component parts, usually mediated 
through the action of other activated caspases. Subsequently, two large and two small 
subunits associate to form the heterotetrameric active enzyme. Caspases can be divided 
into two groups, the initiator caspases (-2, -8, -9 and -10) and the effector caspases (-3, -6, 
and -7) [24, 25]. The initiator caspases have long prodomains that interact with the death 
domains (DDs) of other transmembrane and intracellular proteins and through these 
interactions, transduce a range of pro-apoptotic stimuli into proteolytic activity [24-26]. 
The effector caspases have short prodomains and are directly responsible for the cleavage 
of cellular substrates, causing most of the morphological and biochemical features of 
apoptosis. Substrates which are degraded or inactivated by caspase-mediated cleavage 
include cytoskeletal proteins such as actin, -fodrin, and gelsolin, structural nuclear 
proteins such as the lamins, poly(ADP-ribose) polymerase (PARP) [25, 27], anti-apoptotic 
proteins Bcl-2 and Bcl-xL, and the inhibitor of caspase-activated DNase (ICAD) [28, 29]. 
The cleavage of ICAD releases caspase-activated DNase (CAD) and leads to the apoptotic 
cleavage of nuclear DNA [28, 29].   
There is a large body of evidence that brain ischemia can cause an activation of caspases. 
Up-regulation and activation of caspase-3 was found to precede the neuronal death, 
especially in the hippocampus and caudate-putamen in focal and global models of cerebral 
ischemia [30-32]. Cao at al. [33] reported that transient global ischemia in the rat caused 
caspase-3-mediated cleavage of ICAD, resulting in the apoptotic degradation of DNA by 
CAD. Luo et al. [34] found that deoxyribonuclease activity in transient focal ischemia 
could be prevented by inhibitors of caspase-3.  
The mRNA and protein levels of several procaspases like -3, -6 and -8 were found to 
increase in focal brain ischemia [35]. Also, an activation of caspases-3, -8  and cleavage of 
PARP was observed in the ischemic cerebral tissue [35]. Several studies have shown that 
intra-cerebroventricular injections of selective caspase inhibitors are neuroprotective in 
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transient [36-38] and in permanent ischemia [35]. The caspase activation and, hence 
apoptosis execution is carried out by two main pathological processes: the mitochondrial 
and the death receptor-mediated pathways (for review, see [39]). 
 
1.2 Mitochondrial pathway of apoptosis 
 
The mitochondrial pathway of apoptosis plays a pivotal role in ischemia / reperfusion 
injury [39]. This pathway of cell death is initiated by the release of intramitochondrial 
proteins, such as cytochrome c (cyt c), apoptosis-inducing factor (AIF) and smac / 
DIABLO into the cytosol [40]. A number of mitochondrial changes have been observed 
that lead to release of these substances, which include alterations in mitochondrial 
membrane permeability, largely attributed to the formation of mitochondrial permeability 
transition pore (mtPTP) and disruption of the mitochondrial membrane potential (∆Ψm) 
[41]. Some contradicting studies on isolated mitochondria suggest that the release of cyt c 
might occur also independently of the mtPTP. For example, Andreyev and Fiskum [42] 
showed that mtPTP-mediated cyt c release was found in liver but not in brain 
mitochondrial suspensions. The discrepancy between these studies is not fully understood. 
It was suggested that the induction of mtPTP opening and subsequent cyt c release from 
brain mitochondria might require the intact tissue [42]. 
Translocation of proapoptotic proteins like BAX, Bid, forming oligomeric channels in the 
mitochondrial membranes, is also one of the mechanisms for release of proapoptotic 
factors from the mitochondria (for review, see [43]). The occurrence of such events is well 
documented in experimental models of transient and permanent ischemia [44-48]. A 
universally recognized role of mitochondria in death signaling is the release cyt c from the 
mitochondrial intermembrane space, which is a 13 kD nuclear encoded protein that is 
highly conserved among species and functions as an electron carrier in the electron 
transport chain of mitochondria. It is translocated from cytosol as an unfolded apoprotein 
(apo-cyt c), which contains an integral rather than an N-terminal mitochondrial targeting 
signal, as it is usually the case with most other proteins imported into the mitochondria 
from the cytosol [49]. Only holo-cyt c, containing covalently bound heme (but not apo-cyt 
c that has no heme attached) is competent to carry out the apoptotic signaling [50]. The 
pro-apoptotic role of cyt c is conferred by its interactions with cytosolic factors, which 
include apoptotic protease-activating factor-1 (apaf-1) and caspase-9. Following release of 
cyt c into the cytosol, apaf-1 as well as procaspase-9 are recruited to it, generating a 
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complex, the apoptosome [51-53]. cyt c is critical in this process as in its absence, apaf-1 is 
unable to bind procaspase-9 [51-53]. In this complex, the pro-caspase-9 ultimately gets 
cleaved and thereby activated [51-53]. Active caspase-9, in turn, activates caspase-3, 
which then initiates the process of apoptotic cell death by inducing DNA fragmentation via 
activation of a  DNA breaking enzyme, the CAD [28, 29].  
 
1.3 Oxidative and nitrosative stress  
 
The cascade of events in the pathogenesis of stroke involves oxidative and nitrosative 
stress, i.e., the deleterious effects of reactive oxygen and nitrogen species (ROS / RNS) 
[54-56]. The overload with these substances that include hydroxyl radicals (.OH), 
superoxide anions (O2.-), hydrogen peroxide (H2O2), nitric oxide (NO) and peroxynitrite 
(OONO-) is known to promote DNA damage, peroxidation of lipids, proteins, and 
carbohydrates, blood brain barrier break-down and microglial infiltration into the ischemic 
territory (for review, see [55, 57]). ROS / RNS are considered as upstream triggers of 
mitochondrial damage [58, 59] by inducing the release of cyt c [58, 60]. In ischemia / 
reperfusion, the production of ROS / RNS is particularly significant during reperfusion 
phase [61, 62]. ROS / RNS cause acerbated mitochondrial damage by depleting pyridine 
nucleotides and glutathione, two reducing components that protect mitochondria from 
oxidative damage.  
There are multiple pathways whereby ROS / RNS are produced in the brain. The O2.- 
radicals are produced by electron leakage from the electron transport chain in mitochondria 
and by oxidation of hypoxanthine to xanthine and urate by xanthine oxidase. Other sources 
of ROS / RNS include degradation of free fatty acids by phospholipase A2 into arachidonic 
acid and subsequent oxidation of arachidonic acid by cyclooxygenase and lipooxygenase. 
NADPH oxidase activity in macrophages, neutrophils, and microglia also contribute to 
ROS / RNS production [63].  
Production of NO occurs through conversion of arginine to citrulline by three different 
nitric oxide synthases (NOS): neuronal NOS (nNOS), endothelial NOS (eNOS), and 
macrophage or inducible NOS (iNOS). NO is a vasodilator but it is also a free radical that 
binds to iron and thiol groups of proteins, including metabolic enzymes. It can cause 
nitrosative or oxidative stress when generated in excess amounts. NO can exert its 
pathological effects either by directly acting on its targets or indirectly after combining 
with other reactants. NO cytotoxicity may cause s-nitrosylation of important cytosolic thiol 
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proteins, it induces lipid peroxidation, respiratory chain complex inhibition and 
mitochondrial impairment (for review, see [64]) The inhibition of respiration could 
contribute to the pro-apoptotic effects of NO by membrane potential reduction, ensuing 
activation of the mtPTP and release of  pro-apoptotic factors from the mitochondria. NO. 
and O2.- react very quickly to form ONOO-. The ONOO- is freely diffusible in its 
protonated form, oxidizes thiol groups, induces protein nitrosylation, mitochondrial 
impairment, and decomposes into .OH and NO2 [65].  High Ca2+, high ADP in ischemia / 
reperfusion stimulate excessive mitochondrial O2.- release, as does the addition of NMDA 
to the cell cultures [66]. 
In normal brain tissue ROS / RNS are detoxified by endogenous enzymatic and non-
enzymatic antioxidants including superoxide dismutase (SOD), glutathione peroxidase, 
catalase, thioredoxin and glutathione [56, 67-69]. When the production of  ROS / RNS 
exceeds this endogenous defense capacity, oxidative / nitrosative stress injury ensues (for 
review, see [56, 70, 71]). Mitochondria appear to be both a site of ROS production as well 
as a target of ROS / RNS attack. Mice overexpressing the mitochondrial manganese 
superoxide dismutase (Mn-SOD) displayed less tissue damage and cyt c release after focal 
ischemia than wild-type animals [72]. Consistently, mice with a partial deficiency of the 
Mn-SOD gene displayed increased cytochrome c release and more extensive tissue damage 
[47, 73, 74].  
There is a large body of evidences showing that ROS / RNS are generated after ischemia / 
reperfusion and that they play an important role in the development of brain injury [75-77]. 
It was shown that inhibitors of lipid peroxidation, xanthine oxidase and ROS scavengers or 
iron chelators reduced brain damage [77-79]. Several studies suggest that NO is produced 
in excessive quantities after ischemia / reperfusion and pharmacological blockade as well 
as knock-out mice lacking NOS have reduced the cerebral ischemic damage [80, 81]. 
Hence, the concept of pharmacological supplementation against ROS / RNS with 
antioxidants has become an area of intense research (for review, see [82, 83]). 
 
1.4 Excitotoxicity 
 
Glutamate, the major excitatory neurotransmitter in the brain, plays an important role in 
excitotoxicity. It acts in about 30% of synapses in central nervous system (CNS), it is kept 
in specific vesicles and is released in little doses that take over the receptors and then is 
metabolised by specific enzymes. The sequence of excitotoxicity starts with the excessive 
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extracellular accumulation of glutamate. Extracellular levels of glutamate in experimental 
models of stroke has been reported to increase after ischemic insults [84]. In agreement 
with this, it was shown that a blockade of glutamate receptors reduce the  brain infarction 
in cerebral ischemia [85]. Glutamate acts on three families of receptors (for review, see 
[86, 87]). One family of these receptors (NR1, NR2A, NR2B, NR2C and NR2D) is 
activated by glutamate analogue N-methyl-D-aspartate (NMDA) and collectively referred 
to as NMDA-receptors [86]. Another family of the glutamate receptors includes α-amino-
3-hydroxy-5-methyl-4-isoxalone propionic acid (AMPA) and kainate receptors, which are 
activated by AMPA and by kainate respectively. These two families of glutamate receptors 
are collectively called as ionotropic glutamate receptors as they are directly linked to ion 
channels. The third family of glutamate receptors consists of G-protein coupled receptors, 
the so-called metabotropic receptors, which are subdivided into group I (mGluR1 and 
mGluR5), II (mGluR2 and mGluR3), III (mGluR4, mGluR6, mGluR7 and mGluR8) (for 
review, see [86]). NMDA receptor over-stimulation in relation to excitotoxicity is very 
well studied. For the stimulation of NMDA receptors by glutamate, glycine acts as a co-
agonist. The co-agonistic binding of glycine is important for this receptor to be stimulated 
by glutamate. Its stimulation causes the entry of Ca2+ into the cells as it is directly linked to 
Ca2+ channels. Under normal conditions the cytosolic Ca2+ ([Ca2+]c) is stable and low, 
around 10,000 times lower than the extracellular level. But in pathological conditions like 
ischemia / reperfusion, the over-stimulation of the NMDA receptor causes increased entry 
of Ca2+ into the cells thereby mediating the excitotoxicity and neuronal damage. The 
excess of [Ca2+]c is highly toxic for the cells, promoting cerebral edema formation and 
activation of intracellular self-destruction cascade.  
Ca2+, a cellular messenger that controls important aspects of cell and tissue physiology, can 
be turned into death signals when delivered at a wrong time and at a wrong place [88, 89]. 
Mitochondria eventually decide whether Ca2+ signals are decoded as life or death [90]. 
Scorrano et al. [91] demonstrated that transfer of Ca2+ from ER to mitochondria is required 
for initiation of programmed cell death by some, but not all apoptotic signals. The role of 
Ca2+ as a death trigger was first suggested by Fleckenstein et al., who proposed that the 
entry of excess of Ca2+ into myocytes might be the mechanism underlying the cardiac 
pathology that occurs after ischemia [92]. Subsequent studies emphasized the general 
importance of this observation as both receptor over-stimulation [93] and cytotoxic agents 
[94] were found to cause influx of Ca2+ into the cells. It is now known that Ca2+ dependent 
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processes are interwoven with the main stream apoptosis executors, the caspases and 
recent findings indicate that interfering with the sequestration of Ca2+ into intracellular 
pools can be sufficient to trigger apoptosis [95]. Ca2+ overload and Ca2+ dependent 
processes have been shown to activate and modulate the execution of non-apoptotic cell 
death as well [96].  
 
1.5 Mitochondrial Ca2+ and permeability transition pore 
 
Mitochondria are known to actively participate in [Ca2+]c  regulation [97]. Mitochondria act 
as Ca2+ buffers in the cells by sequestering excess of Ca2+ from the cytosol. However, if the 
intramitochondrial Ca2+ reaches a certain threshold level, it becomes detrimental. [98, 99]. 
Ca2+ enters the mitochondria by the electromotive force, driven by the mitochondrial 
membrane potential (∆Ψm). According to the chemioosmotic theory of Mitchell [100], the 
electron transport in the respiratory chain of mitochondria causes the extrusion of H+, 
creating a large electrochemical difference across the inner mitochondrial membrane that 
creates the ∆Ψm.. The potential generates a net negative charge inside the mitochondria that 
entails the driving force for the Ca2+ to enter into the mitochondria. Ca2+ enters 
mitochondria via the Ca2+ uniporter and exits by exchange with Na+ on the Na+ / Ca2+ 
carrier; thereby maintaining a continuous Ca2+ cycling across the mitochondrial 
membranes (Fig. A) [101, 102]. The continuous Ca2+ cycling maintains the physiological 
mitochondrial Ca2+ pool low. However, under pathological conditions like neuronal death, 
the intracellular Ca2+ get accumulated in higher amounts, thereby exposing the 
mitochondria to high Ca2+ concentrations [97]. Exposure of mitochondria to high Ca2+ 
makes them to buffer much higher amounts of [Ca2+]c that in turn causes mitochondrial 
swelling and release of intra-mitochondrial contents into the medium [98, 99]. This 
pathological process disrupts the mitochondrial Ca2+ cycle and results in a faulty handling 
of Ca2+ by mitochondria. It is now realized that this sequence of events reflects the 
assembly of a proteinacious pore, called the mitochondrial permeability transition pore 
(mtPTP) [96].  
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Fig. A: Figure showing the transport of Ca2+ and H+ inos across the inner mitochondrial membrane 
(NCE: Na+ / Ca2+ exchanger; F1F0: F1F0 ATP synthase; CUP: Ca2+ uniporter; ETC: electron transport 
chain.) 
 
mtPTP allows the release of accumulated Ca2+ as well as of various low and high 
molecular weight compounds from the mitochondria. This process is accompanied by 
osmotic swelling of the mitochondria, collapse of ÉΨm and to the cessation of ATP 
generation. Additionally, the pore formation leads to bursting of mitochondrial membranes 
and production of reactive oxygen species (ROS). Thus, the mtPTP formation represents a 
fundamental pathological process that can initiate pathway of cell death, either by causing 
ATP depletion and energetic collapse [41] or by promoting the release of mitochondrial 
proteins including cyt c that leads the cells into apoptosis (for review, see [59, 103, 104]). 
It is reported that decrease in ATP, oxidative stress and calcium accumulation are the 
major factors that trigger the assembly of mtPTP [105, 106], however high Ca2+ and 
oxidative stress have emerged as major determinants for mtPTP formation [107, 108].  
 
1.6 Molecular composition of mtPTP 
 
The molecular composition of mtPTP remains uncertain. The dominant hypothesis is that 
the mtPTP spans the mitochondrial inner and outer membrane and is composed of proteins 
from both the membranes and the matrix (Fig. B). Inhibitor and reconstitution studies 
implicate that the adenine nucleotide translocase (ANT), located in the inner mitochondrial 
membrane (IMM), is an essential component of the mtPTP [59]. Atractyloside that binds to 
ANT from the cytosolic side induces the pore formation, whereas bongkrekic acid that 
binds to ANT from matrix side, blocks the mtPTP [59]. Recent studies on ANT knock out 
mice showed that mtPTP assembly can also occur without ANT. Voltage-dependent anion 
ETC
F1F0 NCE CUP 
mtPTP 
Ca2+ 
H+
2 Na+Ca2+ 
∆Ψm  
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channel (VDAC) or porin of the outer mitochondrial membrane (OMM) complexes with 
ANT forming the core component of the mtPTP [109, 110]. A critical factor in the 
induction of mtPTP is the interaction of Cyp D to the VDAC-ANT complex. Cyp D is a 18 
kD mitochondrial matrix protein that translocates from matrix to mtPTP during conditions 
of high Ca2+ and oxidative stress [59]. Immunosuppressant cyclosporine A (CsA), has been 
proved to be a strong inhibitor of mtPTP. This is presumably because CsA binds with Cyp 
D, thereby blocking the mtPTP by competing with the effects of Ca2+-cyclophylin for 
occupancy on the transition pore complex [105]. CsA also inhibits the cytosolic 
immunophilin calcineurin. Immunosuppressant FK-506, that inhibits calcineurin but not 
Cyp D, has no effect on mtPTP. Furthermore, an analogue of CsA, N-methyl-valine-4-
cyclosporine that has no effect on calcineurin but readily inhibits the mtPTP. Other 
proteins associated with the pore that are know to increase the pore conductance, include 
hexokinase, creatinine kinase, the peripheral benzodiazepine receptor and pro-apoptotic 
proteins like BAX [59].  
The mtPTP inhibitor CsA is protective in various models of cerebral ischemia in-vitro and 
in-vivo [111-113], suggesting that the inhibition of mtPTP comprises a target for 
pharmacological intervention to prevent cell death in cerebral ischemia.  
 
 
 
(VDAC: Voltage dependent anionic channel; ANT:  adenine necleotide translocase; Cyp D: cyclophilin D; 
BZDR: benzodiazepine receptor ) 
Fig. B: The basic unit of the PT pore is the VDAC–ANT–Cyp-D complex located at contact sites between the 
mitochondrial inner and outer membranes. Other proteins associate with the complex as indicated (Modified 
from: Crompton, M;  Biochem. J. (1999) 341, 233-249) 
Outer membrane 
Cyp D 
Hexokinase BAX BZDR Glycerol kinase
Inner membrane 
VDAC 
ANT 
Creatine kinase 
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1.7 Pharmacological intervention in cerebral ischemia   
  
Despite substantial research into neuroprotection and a remarkable number of positive 
results from different laboratories using rodent models, no neuroprotective agent has been 
conclusively shown to be clinically effective in acute stroke [114]. Except for thrombolytic 
therapy, which is applicable only in a certain cases of stroke [115], current clinical 
management is limited to supportive measures and stroke therapy is at the same stage of 
neuroprotection as 20 years ago. The failure of neuroprotective drugs in clinical situations 
has been tentatively attributed to several factors that include: (a) difficulty in finding 
clinically relevant delivery system to administer compounds intracerebrally over a long 
period of time (b) difficulty in transposing different experimental settings to human 
situations that are characterised by extreme heterogeneity in the etiology, location and 
severity of ischemic strokes (c) lack of experimental evidence for long term protection. 
The development of new therapeutic strategies remains a crucial challenge. The cell death 
pathways, necrosis and apoptosis can no longer be categorized as two exclusive pathways 
in ischemic. It is believed that apoptosis in ischemia is masked by necrotic cell death [15, 
16], so the inhibition of early apoptosis seems to be a potential target to attenuate cellular 
loss in cerebral ischemia. Since, several pathways leading to cell death are activated in 
cerebral ischemia, effective neuroprotection might require a combination of drugs that 
target distinct pathways during the evolution of ischemic cell death. Rational therapy based 
on inhibiting multiple cell death mechanisms might ultimately prove successful in 
neuroprotection. Also newer mechanisms for neuroprotective actions of well 
acknowledged neuroprotectants need to be explored that will make it easy to employ 
effective drug combinations for therapeutic interventions. Also, search for newer 
neuroprotectants may prove beneficial in stroke therapy.  
 
1.7.1 Melatonin 
 
Melatonin, the main secretory product of the pineal gland, is well known for its 
neuroprotective effects that are currently attributed mainly to its free radical scavenging 
and antioxidant properties [116]. Melatonin as a neuroprotectant represents a rational 
approach to stroke treatment and offers a number of potential advantages. It is highly 
effective in preventing neuronal loss in models of brain damage where oxidative stress is 
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involved. The endogenous compound that readily crosses the blood-brain barrier (for 
review, see [116]) was accordingly found to reduce the infarct size and neuronal injury in 
experimental ischemia [117-120]. Furthermore, melatonin reduces oxidative stress and 
rescues dopaminergic neurons in different models of Parkinson’s disease [121, 122]. 
Melatonin protects against the seizures induced by kainate, glutamate and NMDA [123]. 
Supporting the role of melatonin as an endogenous protectant, an aggravation of brain 
damage after ischemia or excitotoxic seizures has been reported in rats that are deficient in 
melatonin production [120]. Besides the direct antioxidant potential, several other 
mechanisms such as interactions with calmodulin [124] are also considered to be involved 
in the melatonin mediated neuroprotection. Melatonin is furthermore reported to directly 
alter the activities of detoxifying enzymes, thereby improving the total antioxidant defense 
capacity of the cells. Thus, systemic treatment with melatonin has been shown to cause an 
increase in the glutathione peroxidase activity in rats [125] as well as the gene expression 
of antioxidant enzymes including Mn-SOD and Cu/Zn-SOD [126]. Moreover, melatonin 
prevents the activation of the transcription factor NFκB [127]. This may be the underlying 
mechanism by which melatonin reduces the expression of the iNOS [128], a major source 
of deleterious reactive nitrogen species like NO or its metabolite ONOO-. 
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1.7.2 Oxyresveratrol 
 
Hydroxystilbenes, naturally occurring polyphenolic compounds, are well-known for their 
free radical scavenging properties [129-131]. Resveratrol, a representative of this group, 
has been widely investigated for its cytoprotective effects in various pathological models 
including experimental cerebral ischemia [132, 133]. Recently it was reported that the 
likewise naturally occurring analogue trans-2, 3’, 4, 5’-tetrahydroxystilbene, 
oxyresveratrol (OXY) is a potent antioxidant [131]. Oxyresveratrol is ready available from 
mulberry wood (Morus alba L.) Despite its better solubility in aqueous solutions and less 
cytotoxicity, yet it is pharmacologically less investigated. Moreover, research has shown 
that OXY is transported into tissues at high rates resulting in a bioavailability of about 50% 
[134] OXY, used as an active compound in dermatology [135, 136] is known to inhibit 
DOPA oxidase activity [137] and cyclooxygenase [137, 138]. It effectively scavenges 
H2O2, NO and the artificial free radical 2,2-diphenyl-1-picrylhydrazyl (DPPH) [131]. 
Moreover, it was shown that OXY selectively kills activated microglia [131] that are 
assumed to aggravate the outcome of cerebral ischemia by a high NO-output pathway and 
the release of cytokines [139]. Such properties and its high solubility in aqueous solutions 
and low general toxicity, makes OXY potentially superior to resveratrol for 
neuroprotective studies. 
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1.8 AIM OF THE STUDY 
 
1.8.1 The aim of this study is based on our initial finding in striatal neurons that melatonin 
inhibits the [Ca2+]c rise after intense NMDA stimulation in a pattern similar to that of CsA. 
This observation raises the question if mtPTP inhibition is one of the mechanisms that 
mediate the neuroprotective effect of melatonin. We hypothesized that melatonin directly 
inhibits the mtPTP and inhibited the mitochondrial apoptotic cascade in transient brain 
ischemia. To prove this hypothesis following questions were addressed. 
 
(a): Does melatonin inhibits the mtPTP patch currents at single channel level?  
 
(b): Following the hypothesis that an inhibition of the mtPTP by melatonin should also 
preserve the ∆ψm, we tested, if melatonin preserves the ∆ψm in a neuronal cell culture 
model of ischemia where mtPTP formation is known to be associated with mitochondrial 
depolarization. 
 
(c): Being an mtPTP inhibitor, melatonin would also block the cyt c release following 
mtPTP formation thereby inhibiting apoptosis. We tested if melatonin inhibits cellular 
distribution of apoptotic markers, namely that of cyt c, caspase-3 and apoptotic-DNA 
fragmentation in a rat transient brain ischemia model.  
 
1.8.2 Oxidative stress is one of the major factors responsible for the evolution of ischemia / 
reperfusion injury. OXY potentially reduces the load of ROS / RNS by either direct 
scavenging effects or by inhibiting the microglial activation, which is one of potential 
sources of NO and its metabolites. In this study, we tested if OXY protects the brain tissue 
against ischemia / reperfusion injury in a Middle cerebral artery occlusion (MCAO) model 
of transient brain ischemia in rats. We also test if this naturally occurring antioxidant 
inhibits the mitochondrial apoptosis in transient brain ischemia, by assessing the cellular 
distribution of cyt c, caspase-3 and apoptotic DNA fragmentation, the markers of apoptotic 
cell death.   
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2 .  M A T E R I A L  A N D  M E T H O D S  
 
 
2.1 In-vivo experiments 
 
2.1.1 Animals 
All the animal protocols used in this study were in accordance with the Animal Health and 
Care Committee of the Land Sachsen-Anhalt, Germany. Male wistar rats weighing 300-
350 g were used in the present study. The animals were kept under a 12h /12h light/dark 
cycle and given free access to food and water. The rats were randomly divided into 
different treatment groups as described below 
 
2.1.2 Surgical procedure for induction of cerebral ischemia 
 
For the induction of cerebral ischemia, the animals were anesthetised with 2 % halothane 
in 50 % N2O / 50 % O2. During the whole surgical period, the body temperature of the 
animals was maintained at 36.5 ± 0.5 °C by the use of a heating pad, controlled by a rectal 
probe. Focal cerebral ischemia was induced by the intraluminal suture method [142] as 
modified by [143]. Briefly, a 3-0 nylon suture (Ethicon, Johnsons & Johnsons Intl, 
Brussels, Belgium) with its tip rounded by heating near a flame and coated with poly-L-
lysine (prepared by dissolving 1mg poly-L-lysine in 1ml of PBS), was introduced into the 
internal carotid artery through a nick given-in the external carotid artery and advanced 17-
20 mm from the common carotid artery bifurcation to block the origin of middle cerebral 
artery (MCA). The suture was left in place for 2 h while the animals were allowed to wake 
up. After 2 h of occlusion, the intraluminal suture was gently removed during a brief 
period of anesthesia to allow reperfusion. In the groups of sham operated rats all surgical 
procedures except the occlusion of the MCA were performed. The animals were then 
returned to their cages and given free access to food and water. 
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2.1.3 Neurological deficit evaluation 
The neurological deficits of the animals were evaluated 24h after reperfusion. The 
neurological scores were given, using two different methods. 
 
Method I: The widely acknowledged method, described by Bederson et al [144] was used. 
Accordingly following scores were given: 
  
Scores  Criteria 
0  Rats that extend both forelimbs towards the floor when suspended by their 
tail held at 1 meter height from the ground and have no neurological deficit. 
 
1  Rats that consistently flex the forelimb contralateral to the injured 
 hemisphere, posture varies from mild wrist flexion and shoulder adduction 
with internal rotation of the shoulder. 
  
2  Rats that showed reduced resistance to the lateral push when placed on a 
coarse plastic coated paper and have neurological deficit 1. 
 
3  Rats that showed circling behavior consistently towards the paretic side and 
have neurological deficit 1 & 2.  
 
Method II (Spontaneous movements): Spontaneous motor activity (SPMA) was 
evaluated by placing the rats in their normal environment (cage) and were observed for 5 
minutes. The scores were given as follows: 
  
Scores  Criteria  
0  Rats moved in the cage and explored the environment. 
  
1  Rats moved in the cage but did not reach all sides and generally hesitated to 
move.  
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2  Rats barely moved in the cage and showed postural abnormalities  (Curved 
towards the paretic side). 
 
3  Rats unable to move and have posture curved towards the paretic  side.  
 
 
2.1.4 Infarct assessment 
 
For evaluation of infract volume, 2, 3, 5-triphenyltetrazolium chloride (TTC) staining 
method was used [145]. The animals were euthanised 3 days after reperfusion, under 
halothane anesthesia followed by decapitation. The brains were rapidly dissected out and 
the forebrains were cut into six 2-mm thick coronal sections using a rat brain matrix 
(Activational Systems Inc. Michigan, USA). The sections were then incubated in a 2% 
TTC solution (prepared in PBS) at 37 °C for 15 min. The live tissue stained red while the 
infracted tissue did not stain and remained pale. After TCC staining, the sections were 
fixed in 10% buffered paraformaldehyde (PFA). The images of the TTC-stained sections 
were acquired by scanning after 24 h of PFA fixation, by a high resolution scanner 
(Hewlett Packard Scanjet 6100C/T). The mean infarct area of each section was calculated 
as the average of the area on the rostral and the caudal side. Total infarct volume was 
calculated by adding the mean-area of each section and multiplied by 2 mm (thickness of 
the sections). The volume obtained was expressed in mm3. 
 
2.1.5 Immunohistochemistry 
 
For assessing the cytosolic changes in apoptotic markers and for assessment neuronal 
injury at cellular level, immunohistochemical studies were carried out. Accordingly 
cytosolic changes in cyt c and caspase-3 were studied. Along with cyt c and caspase-s, 
alterations in the MAP-2 and NeuN, markers for neuronal degeneration were also studied. 
Subsets of four animals in each group were deeply anaesthetised with a mixture of Domitor 
and ketamine hydrochloride and were transcardially perfused with 100 ml of saline 
followed by 300 ml of 4 % paraformaldehyde (PFA) and 0.2% glutaraldehyde in PBS. 
Following post-fixation in 4 % PFA, the brains were cryoprotected in 0.5 M sucrose for 24 
h followed by 1.0 M sucrose for 72 h at 4°C. The brain samples were then cut into 25 µm 
thick coronal sections and the free floating sections were rinsed with PBS and then 
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incubated in blocking buffer (10% fetal calf serum (FCS) in PBS with 0.3 % Triton X-100) 
at room temperature for 1 h to block non-specific binding sites. The sections were then 
incubated with the primary antibodies (diluted in PBS with 0.3% Triton X-100 and 1% 
FCS) overnight at 4 °C. The following antibodies were used: rabbit anti-cytochrome c, 
1:200 (Santa Cruz Biotechnology, CA, USA), rabbit anti-caspase 3, 1:200 (Santa Cruz 
Biotechnology, CA, USA), monoclonal anti-MAP 2, 1:1000 (Sternberger, Maryland, USA) 
and anti-NeuN, 1:500 (Chemicon, CA, USA). Primary antibody binding was detected by 
incubating the sections with fluorescent conjugated anti-rabbit (1:500, Alexa 546, 
Molecular Probes, Leiden, Netherlands ) or anti-mouse (1:500, Alexa 488, Molecular 
probes, Leiden, Netherlands) secondary antibodies (diluted in PBS) for 2 h at room 
temperature. In control sections, the buffer was added instead of primary antiserum. LSM 
Pascal confocal microscope (Carl Zeiss, Germany) was used for visualisation of the 
immunostained sections. 
 
2.1.6 Assessment of DNA fragmentation 
 
For assessing DNA fragmentation, a monoclonal antibody (Apostain, Alexis Biochemicals, 
Grunberg, Germany) was used. The Apostain method was followed as provided by the 
manufacturer with some modifications. Accordingly, the perfusion fixed brains with 4 % 
PFA were post-fixed in the same fixative for 24 h and thereafter cut into 25 µm thick 
frozen sections. The sections were then taken up onto the superfrost slides and heated in 50 
% formamide to yield single stranded DNA (ssDNA) fragments. The slides were then 
incubated with the monoclonal antibody to ssDNA (1:50) for 30 min at 37 °C to label the 
ssDNA fragments. The primary antibody binding was detected by incubating the sections 
with horse-radish peroxidase-conjugated IgM rat monoclonal anti-mouse secondary 
antibody (Zymed, CA, USA, diluted 1:50 in PBS) and counterstained with hematoxyline. 
The darkly-stained apoptotic cells were visualized in transmission light mode using the 
LSM Pascal confocal microscope (Carl Zeiss, Germany).  
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2.2 In-vitro experiments 
 
2.2.1 Preparation of primary neuronal cultures 
 
Primary neuronal cell cultures were prepared from mouse embryo-striatum, taken out from 
15 days old pregnant mice as described [146]. The mother mice were anesthetised under 
halothane inhalation and the fetus were taken out of their womb in sterile PBS under a 
sterile hood. The heads were separated from the body and the brains were dissected out 
from the foetus heads. The dissected out brains were put in Dulbecco’s modified Eagle’s 
medium (DMEM, Sigma Chemicals, Deisenhofen, Germany) containing 10 % fetal calf 
serum (FCS). Thereafter the striatal regions, free from meninges were taken out from the 
dissected fetal brains and dispersed in DMEM containing 10 % FCS. After dispersion of 
the tissue, the FCS containing DMEM was washed with serum free DMEM, supplemented 
with B27 nutrients (1:50) and streptomycin/ penicillin (1:500). 2ml aliquots of cell 
suspension were plated on poly-D-lysine coated glass cover slips (22mm) in 35 mm petri 
dishes at a final density of 3.5 x 106 cells per ml. The cells were cultured in an incubator at 
37 °C in a humidified atmosphere containing 5 % CO2 in air. 
 
2.2.2 Preparation of glass cover slips for Neuronal cultures 
 
0.1 % solution of poly-D-lysine was prepared by dissolving 1 mg of poly-D-lysine in 1 ml 
of 0.15 M boric acid (prepared in PBS). 22 mm glass coverslips were incubated in the 
poly-D-lysine solution for 1 h and thereafter rinsed with sterile distilled water. The 
coverslips were then kept for drying in an incubator till use. 
 
2.2.3 Intracellular Ca2+ measurements by fluo-4 imaging 
 
Cell cultures were loaded with 2.5 µM fluo-4 AM (Molecular Probes, Leiden, Netherlands, 
stock solution prepared in a 20 % pleuronic acid in DMSO, for 45 min at 37 °C. After dye 
loading, the cultures were transferred into a stainless steel chamber (Atto-fluor, 2 mL 
volume) that was mounted on a thermostatically controlled stage (37 °C) on an inverted 
confocal laser scanning microscope (AXIOVERT, LSM PASCAL, Zeiss, Germany). Cells 
were observed using a Zeiss 63x oil immersion lens. For imaging of Ca2+-sensitive fluo-4 
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fluorescence, excitation light was provided by an argon laser at 488 nm. Fluo-4 
fluorescence emission, filtered at 505 nm long-pass, was recorded using the 
photomultiplier of the LSM Pascal. Image acquisition frequency was set at 1 image per 10 
s. Cells were superfused with Hepes-buffered salt solution (HBSS) containing (in mM): 
137 NaCl, 5 KCl, 20 HEPES, 10 glucose, 1.4 CaCl2, 3 NaHCO3, 0.6 Na2HPO4, 0.4 
KH2PO4 at pH 7.4, at a rate of 2 ml / min using a peristaltic pump (Gilson). After mounting 
the cells on the microscope the cultures were superfused for 5 min with HBSS to wash out 
excess dye. Then the sequential imaging was started and the cultures were further perfused 
with buffer alone for 100 s to obtain a steady baseline. Cultures were then subjected to a 
continuous application of 200 µM NMDA (Alexis Biochemicls, Grunberg, Germany). In 
two other subsets of experiments either CsA (2 µM, Alexis Biochemicals, Grunberg, 
Germany) or melatonin (100 µM, Sigma Chemicals, Deisenhofen, Germany) was added to 
the perfusion-buffer 20 s after the onset of the NMDA stimulation. Images from the 
cultures were collected for 20 min of the NMDA application. Analysis of fluorescence 
intensity was performed off-line after image acquisition by averaging intensity values 
within boxes overlying cell somata in the images using the imaging software of the Zeiss 
LSM. Data were normalized and average image intensities were calculated.  
 
2.2.4 Oxygen-glucose deprivation and mitochondrial depolarization 
 
Cell cultures were subjected to 3 h oxygen-glucose deprivation (OGD) followed by 30 min 
reperfusion. For this purpose, the culture medium was washed with HBSS buffer to 
remove all the glucose-containing-medium. Then OGD was initiated by changing the 
medium of the cultures to glucose-free DMEM (Gibco Invitrogen, Karlsruhe Germany) 
that was first bubbled for 20 min with a mixture of 5 % CO2 and the rest N2 to remove all 
the dissolved O2. The cultures were then immediately transferred into an incubator with a 
humidified hypoxic atmosphere containing 5% CO2, 1 % O2 in N2, maintained at 37 °C. 
After two hours, the OGD in the cultures was terminated by re-supplying the glucose-
containing DMEM and transferring them back into an incubator with a normal atmosphere 
containing 5 % CO2 in air.  
For assessing the mitochondrial depolarization, the control and OGD-subjected cultures 
were incubated with 100 nM tetramethylrhodamine methylester (TMRM, Molecular 
Probes, Leiden, Netherlands) at 37 °C for 20-30 min. TMRM was added at time after the 
OGD termination. For imaging the TMRM fluorescence, excitation was set at 543 nm and 
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emission was filtered at 570 nm long-pass and the filtered fluorescence light was recorded 
by photomultipliers. Within one set of experiments, gain and offset of the imaging program 
were kept constant. Very low laser intensity was used to avoid the photo activation of the 
dye. 
 
2.3 Patch clamp of the mtPTP 
 
To test the direct effect of melatonin on the mtPTP, we studied single-channel currents 
through the mtPTP by means of the patch-clamp techniques with mitoplasts, prepared from 
isolated liver mitochondria, applying different solutions by a flow system.  
 
2.3.1 Preparation of mitoplasts 
 
Liver of male Sprague-Dawley rats were cut in small pieces, homogenized by means of a 
teflon-pistle and centrifuged for 5 min at 600×g. The resulting supernatant was centrifuged 
again for 4 min at 5100×g. The pellet obtained was resuspended in an isolation medium 
containing 250 mM sucrose, 1mM K-EDTA (pH 7.4) and centrifuged for 10 min at 12300 
× g. The final pellet containing the mitochondria was resuspended in storage medium and 
stored on ice for a maximum of 36 h. Mitoplasts were prepared by a hypo-osmotic 
treatment with the hypotonic buffer containing, 5 mM potassium-HEPES, 0.2 mM CaCl2 
(pH 7.2). After one-minute incubation at room temperature, the isotonicity was restored by 
addition of hypertonic medium: 750 mM KCl, 80 mM K-HEPES, 0.2 CaCl2 mM (pH 7.2). 
 
2.3.2 Electrophysiology 
 
For patch-clamp experiments borosilicate glass pipettes (Clark, Pangbourne, UK) were 
polished to yield resistances of 12-17 MΩ. Free-floating mitoplasts were approached by 
the pipette using an electrically driven micromanipulator. The mitoplasts were moved to 
their final position at the pipette tip by gentle suction. Gigaseals of about 1.5 GΩ were 
formed spontaneously or by additional suction. Experiments were done in the mitoplast-
attached mode. Currents were recorded by an L/M-EPC-7 amplifier (HEKA electronics, 
Lambrecht, Germany). The currents were low-pass filtered by a 4-pole Bessel filter at a 
corner frequency of 0.5 kHz. Data were recorded at a sample frequency of 2.5 kHz by 
means of the pClamp software (Axon instruments, Foster City, CA) which was also used 
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for processing of the data. Melatonin in different concentrations (0.25, 0.8, 1, 10, 100 µM) 
was added through the glass capillaries of a peristaltic-pump driven flow system. Potentials 
given are measured at the inner side of the membrane. Inward currents are always depicted 
downwards in the traces. The probability that the channel is in an open state (Po) was 
determined by an all points analysis according to the following equation: 
 
            (A1 * B1) + (A2 * B2) + ... + (An * Bn) 
Po = --------------------------------------------------      
            Bmax (A0 + A1 + A2 + ... + An) 
 
where Po is weighted by the different amplitudes of the sub-states (Bn), An is the area 
under the Gaussian curves for the closed state and the different open states [147]. 
 
2.4 Statistical analysis 
 
Data are shown as (mean ± SEM). For statistical analysis, one way analysis of variance 
(ANOVA) was applied followed by Dunnett’s Multiple Comparison test. For the results 
obtained with NMDA induced [Ca2+]c rise, data were collapsed at every 100 s time point 
after onset of NMDA application. These data were then treated with two-way ANOVA 
followed by Tukey’s-t-test. p< 0.05 was considered to be statistically significant. 
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2.5 EXPERIMENTAL DESIGN 
 
2.5.1 Direct inhibition of the mitochondrial permeability transition pore: a possible 
mechanism responsible for anti-apoptotic effects of melatonin 
 
2.5.1.1 Assessment of the effect of melatonin on NMDA-induced intracellular Ca2+ 
alterations by fluo-4 imaging 
 
For the assessment of NMDA-induced intracellular Ca2+ changes by fluo-4 imaging, 
primary neuronal cultures were divided into different groups. In one group, NMDA 
treatment was started at 100 sec after the start of image acquisition. NMDA dissolved in 
HBSS was infused continuously for the whole of the experiment. In other two groups of 
cultures, either melatonin or CsA were continuously infused along with NMDA at 20 s 
after the start of NMDA application (Scheme 1).  
 
 
 
 
 
 
 
 
 
Scheme 1: Protocol for Ca2+ imaging. After mounting the Fluo-4 loaded culture on the microscopic stage, the 
culture was perfused for 0-100 sec with buffer alone. At 100 s continuous infusion of NMDA was started. In 
other subsets of experiments, either melatonin or CsA was infused at 20 s after NMDA infusion. The 
experiment was run for a total of 1200 s.   
NMDA +  Melatonin or CsA Buffer 
0 S 100 S 1200 S
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2.5.1.2 Assessment of the effect of melatonin on OGD and mitochondrial 
depolarisation 
 
In order to access the effect of melatonin on mitochondrial depolarization in oxygen-
glucose deprived neurons, the cultures were divided into following groups. 
First group: cultures were incubated with TMRM alone and no OGD was subjected. 
Vehicle 10 % alcohol 4 µl were also added to the culture. This group served as control for 
other OGD-subjected cultures.  
Second group: OGD was subjected for three hours followed by reperfusion. Here again 
vehicle 10% alcohol (4 µl) was applied. 
Third group: melatonin was added and the cultures were subjected to the OGD protocol. 
Fourth group: only melatonin was added and no OGD was subjected to the cultures.  
Fifth group: CsA (2 µl) was added and the cultures were subjected to the OGD protocol 
(scheme 2)  
 
 
 
 
 
Scheme 2: Protocol for ODG experiments: Melatonin or CsA was treated in the cultures at 0 h of OGD. At 3 
h OGD was terminated and melatonin or CsA was treated again. TMRM was loaded into the cultures shortly 
after the OGD termination. After 30 min reperfusion, cultures were analysed for mitochondrial TMRM 
uptake, using confocal Zeiss Microscope.  
Reperfusion 
TMRM
0 h 3h 3.30h
OGD
   Melatonin  
    or CsA 
   Melatonin  
    or CsA 
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2.5.1.3 Assessment of neuroprotective and antiapoptotic effects of melatonin 
 
To test the antiapoptotic and neuroprotective effects of melatonin in the rat middle cerebral 
artery occlusion (MCAO), the animals were kept under a 12 h /12 h light/dark cycle and 
were given free access to food and water. The rats were randomly divided into four 
treatment groups: “Sham + Vehicle” (injection of vehicle, no occlusion), “Sham + Mel” 
(rats treated with melatonin only and no occlusion was performed), “MCAO + Vehicle”  
(MCAO was performed and vehicle was given in place of the drug), and “MCAO + Mel ” 
(MCAO was applied and the animals were treated with melatonin). In order to make the in-
vivo ischemia conditions more close to the clinical situation, MCAO occlusion with 
intraluminal suture method was used. The MCA was occluded for 2 h followed by 
reperfusion. For evaluation of neurological deficits, animals were evaluated 24 h after 
reperfusion for neurological function tests, the infarct volume was evaluated 3 days after 
reperfusion. Subsets of animals were sacrificed at 4 h and 24 h of reperfusion for the 
assessment of the cytosolic changes in different apoptotic, Mn-SOD, glutathione 
peroxidase activity and cell death markers. 
 
2.5.1.4 Melatonin in-vivo treatment 
 
In order prepare melatonin solution for in-vivo treatment, the drug was dissolved in 10 % 
alcohol and was injected intraperitoneally (i.p) twice into the rats; at the time of occlusion 
and at the time of reperfusion. The drug was first dissolved in 100 µl of absolute alcohol 
and then diluted with normal saline to get a final concentration of 10 % alcohol. Each 
animal was injected a volume of 1ml / kg of body weight. 
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2.5.2 Oxyresveratrol (trans-2, 3’, 4, 5’-tetrahydroxystilbene) is neuroprotective and 
inhibits the apoptotic cell death in transient cerebral ischemia 
 
2.5.2.1 Assessment for neuroprotective effects of Oxyresveratrol 
 
For this purpose, the animals were randomly divided into 10 treatment groups (n =10 for 
each group): “Sham + Vehicle” (sham-operated animal without MCAO and treatment with 
vehicle only) “Sham + OXY 2” (sham-operated animals, treated with 2 mg OXY), “Sham 
+ OXY 10” (sham-operated animals, treated with 10 mg OXY), “Sham + OXY 20” (sham-
operated animals, treated with 20 mg OXY), “Sham + OXY 30” (sham-operated animals, 
treated with 30 mg OXY), “MCAO + Vehicle” (animals with MCAO and vehicle 
treatment), “MCAO + OXY 2” (animals with MCAO and 2 mg / kg OXY treatment), 
“MCAO + OXY 10” (animals with MCAO and 10 mg / kg OXY treatment), “MCAO + 
OXY 20” (animals with MCAO and 20 mg / kg OXY treatment) and “MCAO + OXY 30” 
(animals with MCAO and 30 mg / kg OXY treatment).  
 For evaluation of neurological deficits, animals were evaluated 24 h after reperfusion for 
neurological function tests, the infarct volume was evaluated 3 days after reperfusion, in a 
similar way as that of melatonin-treated rats. Subsets of animals were sacrificed at 4 h and 
24 h of reperfusion for the assessment of the cytosolic changes in different apoptotic and 
cell death markers. 
 
2.5.2.2 Oxyresveratrol preparation and treatment 
  
OXY was prepared from mulberry wood as described previously [131]. The purity of the 
compound was confirmed by TLC, HPLC, and its melting point (mp = 199 – 200 oC, 
mp Lit.= 201 oC [148]. The 1H- and 13C NMR-spectral data (UV spectrum: λmax = 328 nm, 
logε = 4.329) of the purified OXY were consistent with that of the literature [149, 150].  
OXY (30, 20, 10 and 2 mg / kg body weight in a total volume of 1 ml in 30 % alcohol) or 
equal volumes of vehicle were administered intraperitoneally (i.p.) in animals twice: at the 
time of occlusion and at the time of reperfusion.  
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3 .  R E S U L T S  
 
 
3.1 Direct inhibition of the mitochondrial permeability transition pore: a possible 
mechanism responsible for anti-apoptotic effects of melatonin in transient brain 
ischemia 
 
3.1.1 Melatonin reduced the sustained [Ca2+]c increase in primary neuronal cultures 
exposed to NMDA 
 
We first studied if melatonin modulates the NMDA-induced [Ca2+]c rises as measured by 
fluo-4 confocal imaging in mouse striatal neurons. Upon stimulation of striatal neurons 
with 200 µM NMDA, we observed a fast initial increase in the fluo-4 fluorescence from a 
baseline intensity of 103.4 ± 4.3 (average of single cell arbitrary intensity values ± SEM, 
n=5 cultures) to a level of 282.3 ± 22.5 immediately after exposure to NMDA (Fig. 1). The 
increased fluorescence, indicating an increase in [Ca2+]c did not return to the baseline level 
but remained at a sustained plateau level for the whole experiment. After 18 min of NMDA 
application, the fluorescence was still high at 284.3 ± 16.2.  
When cyclosporine (CsA, 2 µM) was added to the NMDA-containing superfusion solution, 
the neurons exhibited again a fast initial increase in the fluorescence, peaking at similar 
levels (297.3 ± 7.2, n=5 cultures). However, the fluo-4 fluorescence did not remain at the 
plateau levels with CsA treatment, instead started to decline (Fig. 1). At 5 min of CsA + 
NMDA application a significant decrease in the NMDA-induced sustained fluorescence 
was observed (207.7 ± 15.2, p <0.05) and at 18 min of CsA application the values declined 
to 188.8 ± 23.0 (p<0.05). When melatonin (100 µM) was added to the NMDA-containing 
superfusion solution, the fluorescence plateau started to decline again in a similar pattern 
as seen with CsA (Fig. 1). At 5 min of melatonin + NMDA application the fluorescence 
values significantly decreased from 281.9 ± 12.6 to 230.3 ± 14.7 (p <0.05) and at 18 min of 
melatonin application to 181.5 ± 11.9 (p <0.05). 
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Fig. 1: Melatonin decreases NMDA-induced intracellular calcium levels: 
Neuronal cultures were loaded with the Ca2+-sensitive fluorochrome fluo-4 and time series of confocal 
images were recorded to monitor the fluorescence intensities. NMDA was applied alone (200 µM, blue line) 
and or together with CsA (2 µM, green line) or melatonin (100 µM, red line). The black lines above the 
graph indicate the duration of the treatments. 
 
A : Depicted are the average fluorescence intensity traces of the different treatment groups reflecting the 
intracellular Ca2+ levels. The traces were obtained by analysing the average pixel fluorescence intensity 
within boxes drawn over single cell somata for each image of the time series. NMDA alone shows a rise in 
[Ca2+]c in neurons that sustained at a plateau level throughout the continuous NMDA application. Both, 
melatonin and CsA decreased the sustained rise in [Ca2+]c in the NMDA-stimulated neurons. Normalized data 
are expressed as mean ± SEM, n= 5 cultures for each group.  
 
B: Representative images of the fluo-4-loaded cultures. The left column depicts the baseline fluorescence 
before the NMDA application, the two other columns show the elevated fluorescence during the NMDA-
exposure. 
The upper row (NMDA alone) shows the sustained rise in [Ca2+]c after NMDA application. The middle row 
(NMDA + Mel) indicates that although these neurons displayed an initial high [Ca2+]c level after the NMDA 
exposure onset, the fluorescence decreased in the presence of melatonin. The lower panel of images shows a 
similar effect of CsA on the NMDA-induced [Ca2+]c level as seen with melatonin. 
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3.1.2 Melatonin inhibited the mtPTP 
 
We investigated if melatonin has a direct inhibitory effect on the mtPTP. For that purpose, 
we recorded the mtPTP channel currents from patches of the inner mitochondrial 
membrane. The recordings displayed a characteristic activity of the mtPTP with an 
extremely large single channel conductance of more than 1 nS and a large variety of sub-
conductance states that could all be reversibly blocked by 1 µM CsA, (Fig. 2A) as 
described before [147]. Melatonin inhibited the Po of mtPTP (Fig. 2C) in a dose dependent 
manner ranging from 100 µM to 200 nM. The respective concentration response relation is 
shown in Fig 3C. The best fit by means of the Hill equation was calculated with an IC50 of 
0.8 µM and a Hill coefficient of 1. A maximum decrease in the Po to only 80% reflects the 
fact that the effect of melatonin even at higher concentration is gradual and as the initial 
records also contribute to the mean Po, the mean values do not decline to zero, instead 
saturate at 80% (Po / Po max = 0.2). This effect was reversible upon washout in the control 
solution (Fig. 2B, 4th trace). 
 
Fig. 2: Melatonin inhibits the mtPTP currents at single channel level: 
A: Representative traces of mtPTP activity (control, 1st trace), with CsA application (2nd and 3rd trace) and 
after switching back to control solution (4th trace). 
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B: Effect of melatonin on single channel currents recorded from the mtPTP of the mitoplast membrane:  
Shown are the representative traces of mtPTP activity with a representative 1 µM melatonin application. The 
base line mtPTP activity (control, 1st trace) was blocked  by 1µM Melatonin (2nd and 3rd trace,  at 10 s and 72 
s, respectively, after switching to melatonin) which was reversible (4th trace, after switching to control). 
Dotted lines give zero-current level. Holding potential (Eh) +20 mV.   
 
C: Concentration-response curve for the normalized open propability (Po) under the influence of melatonin 
at Eh = +20 mV:  
Po was estimated by all-point analysis of the single channel data in 1 min segments from each experiment, 
starting one minute after the addition of melatonin. Mean Po were calculated from 2 independent experiments 
at each concentration. Data are shown as mean ± SEM and the curve was calculated by means of the Hill 
equation (Hill coefficient: 1) with a half-maximum Po (IC50) at 0.8 µM.  
 
 
 
 
3.1.3 Melatonin prevented mitochondrial depolarisation after OGD in primary 
neuronal cultures 
 
We used the potentiometric fluorescent dye TMRM to monitor its uptake in OGD-
subjected mouse striatal neurons in the presence or absence of CsA or melatonin as a 
measure for the integrity of the ∆ψm. Fluorescence images of TMRM-incubated cultures, 
obtained after 3 h of OGD and 30 min glucose-oxygen resupply, showed only little TMRM 
fluorescence in mitochondria-like structures, an indication that the mitochondria were 
largely depolarised after the insult (Fig 3b). The few structures that exhibited TMRM 
fluorescence displayed an unusual round short shape whereas the mitochondria-like 
structures in control cultures that did not undergo the OGD procedure showed an intensive 
fluorescence (Fig. 3a). When the OGD-subjected cultures were additionally treated with 2 
µM CsA the loss of TMRM-labelled mitochondria-like structures was partially reversed 
(Fig 3e). Similarly, a treatment with 100 µM melatonin prevented the loss of TMRM 
uptake due to OGD. The mitochondrial shape was less disrupted in these cultures (Fig. 3c). 
Melatonin or CsA per se did not alter the TMRM uptake into the neurons that were not 
subjected to OGD (Fig. 3d). Furthermore we tested the TMRM-uptake into the 
mitochondria in control cultures that were treated with Verapamil (5 µM) 5 min before 
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TMRM incubation to inhibit the multi drug resistance pump (MDR). We found that the 
TMRM-uptake in verapamil treated cultures was not different from that of control cultures, 
treated with either vehicle, melatonin or CsA (Fig. 4).  
 
 
 
 
Fig.  3: Melatonin preserves the rate of TMRM uptake after OGD: 
 Representative pictures showing an overlay of a phase contrast image and an image of the TMRM 
fluorescence. Red colour shows the TMRM-loaded mitochondria, indicating an intact ∆Ψm. The images were 
obtained after the cultures were subjected to 3 hrs OGD followed by 30 min oxygen-glucose resupply. 
TMRM was added to the culture medium at the time of oxygen-glucose resupply.  
(a) shows a control culture with strongly stained mitochondria-like structures. In (b) an OGD-treated culture 
is shown that has almost completely lost the ability to take up TMRM into the mitochondria indicating a loss 
of ∆Ψm. OGD-subjected cultures (c) that contained melatonin (100 µM) in the medium, in contrast, retained 
the capacity to load TMRM. Melatonin alone (d) did not alter the TMRM uptake in control cultures. 
Analoguous to melatonin, a treatment with 2 µM CsA (e) also prevented the loss of ∆Ψm as indicated by the 
mitochondrial uptake of TMRM in some cells.  
Vehicle + Control 
Mel + Control 
Vehicle + OGD 
CsA + OGD 
d 
b c 
e 
a 
Mel +  OGD 
50 µ m 
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Fig. 4: TMRM uptake in control cultures, (a) treated with either vehicle, (b) verapamil (5µM), (c ) melatonin 
(100 µM), (d) CsA (2 µM) (e) verapamil 5 µM + melatonin 100 µM  or (f) verapamil 5 µM + CsA 2 µM . In 
vehicle-control culture (a) well defined mitochondrial-TMRM uptake is seen. Control cultures (b) treated 
with verapamil (5 µM), incubated 5 min before TMRM application, showed a similar TMRM uptake as seen 
in vehicle-control cultures (a). There is no difference in TMRM-staining between verapamil-treated cultures 
(b) or melatonin-treated cultures (c ) or CsA-treated cultures (d) and vehicle control cultures (a). Also in 
cultures, where verapamil was treated in combination with melatonin (e) or in combination with CsA (f), no 
difference is observed in TMRM staining as compared to vehicle-control cultures (a).  
Control + Vehicle Control + Verapamil Control + melatonin 
Control + CsA Verapamil+ melatonin Verapamil+ CsA 
a b c 
d e f 
RESULTS 35
 
3.1.4 Anti-apoptotic effects of melatonin in the MCAO model of cerebral ischemia 
 
3.1.4.1 Melatonin prevented the release of cyt c release from mitochondria 
 
We explored the effect of melatonin treatment on the cytosolic cyt c immunoreactivity in 
brain sections of the infarct area in MCAO rats, using immunohistochemistry. MCAO 
followed by reperfusion in the “MCAO + Vehicle” group caused a pronounced increase in 
the cytosolic cyt c immunoreactivity at 4 h as well as 24 h after the reperfusion (Fig. 5A). 
At 4 h, the cytosol was strongly stained for cyt c immunoreactivity. At 24 h after 
reperfusion, the cyt c immunoreactivity extended even to the intercellular space (Fig. 5A) 
indicating massive degeneration of the cells and shedding off the intracellular contents into 
the intercellular spaces. In contrast, the “Sham + Vehicle” rats showed a profile cyt c 
staining at both 4 h as well as 24 h (Fig. 5A) that was indicative of intact mitochondria. 
When MCAO-subjected animals were treated with melatonin “MCAO + Mel”, the 
cytosolic cyt c immunostaining as well as the intercellular cyt c staining signals decreased 
both at 4 has well as 24 h (Fig. 5A). 
 
3.1.4.2 Melatonin prevented caspase-3 activation 
 
At 4 h of occlusion, sections of “MCAO + Vehicle” rats showed a massive activation of 
caspase-3 in the ischemic cortex as compared to the “Sham + Vehicle” rats (Fig. 5B) that 
was still detectable at 24 h after reperfusion but not localised in well-defined cellular 
compartments (Fig. 5B). Upon melatonin treatment, the caspase-3 activation was 
drastically reduced in “MCAO + Mel” rats both at 4 h and 24 h (Fig. 5B). No changes in 
caspase-3 staining were observed in “Sham + Mel” rats when compared to “Sham + 
Vehicle” rats. 
 
3.1.4.3 Melatonin reduced apoptotic DNA fragmentation 
 
In “MCAO + Vehicle” rats, the Apostain label was observed in the nuclei of a large cell 
population. Such Apostain-positive cells showed a characteristic morphology of apoptotic  
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cells with shrunken structures. The number of Apostain-positive cells were reduced by 
melatonin in “MCAO + Mel” rats (Fig. 5C), showing an anti-apoptotic effect of melatonin. 
 
Fig. 5: Melatonin inhibited the apoptotic cell death in MCAO rats: 
A: Cytosolic cyt c immunoreactivity is decreased in MCAO brain tissue upon melatonin treatment: 
Representative pictures of the cyt c immunostaining in the MCA-supplied cortex obtained at 4 h (upper 
panel) or 24 h (lower panel). No specific cytosolic immunostaining is seen in the “Sham + Vehicle” rats, both 
at 4 h and 24 h.  Characteristic cyt c labelling in the cytosol of cells is observed after 4 h and 24 h in the 
“MCAO + Vehicle” rats. After 24 h the staining is seen in the intercellular spaces indicating the presence of 
cell debris. Melatonin treatment greatly reduces the cytosolic cyt c immunostaining in “MCAO + Mel” rats 
both at 4 h as well as 24 h.  
 
B: The MCAO induced caspase-3 immunoreactivity is reduced by melatonin:  
Corresponding caspase-3 immunofluorescence of the MCA-supplied cortex in the sections adjacent to those 
seen in A. No activation of caspase-3 is seen in “Sham + Vehicle” rats while in vehicle treated MCAO rats, 
most of the cells show an increased caspase-3 immunostaining at 4 h. At 24 h an increased and patchy 
caspase-3 immunostaining is seen in “MCAO + Vehicle” rats. Melatonin treatment decreases the caspase-3 
activation both at 4 h and 24 h after ischemia “MCAO + Mel” rats. 
 
C: Melatonin protects against MCAO-induced DNA fragmentation: 
Images of Apostain-labelled cortices, indicating the presence of apoptotic ssDNA. In “Sham + Vehicle” rats, 
no staining is observed while in the “MCAO + Vehicle” rats, most of the cells are Apostain-labelled. The 
darkly stained cells are shrunken and have a characteristic apoptotic-like appearance. Melatonin decreased 
the number of apopstain-positive cells in “MCAO + Mel” rats. 
 
 
3.1.5 Melatonin reduced the MCAO-induced brain damage 
 
3.1.5.1 Decrease in the infarct volume 
 
TTC staining of brain slices obtained from “MCAO + Vehicle” rats showed reproducible 
and readily detectable lesions in the areas that are supplied by MCA, at 3 days after the 
reperfusion (Fig. 6A1). The lesions were present both in the lateral striatum and the 
overlying cortex. Melatonin, when given at the onset of occlusion and reperfusion in 
“MCAO + Mel” rats, reduced significantly the infarct volume to 147.0 ± 10.4 mm3, 
(p<0.05, n=10) as compared to “MCAO + Vehicle” rats (290.0 ± 13.5 mm3, n=10, Fig. 
6A2).  
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Fig. 6: Melatonin reduces the infarct volume: 
A1: TTC-stained coronal sections from representative animals that received either vehicle (10% ethanol) or 
melatonin (10mg/kg, i.p.) both at the time of occlusion as well as at the time of reperfusion. The animals 
were euthanised 3 days after occlusion. Infarcts are observed as pale regions involving striatum and overlying 
cortex. Note that the infarct area in the melatonin-treated animal is substantially reduced. 
 
A2: Statistical analysis of infarct volume: 
Reproducible infarct volumes are observed in the “MCAO + Vehicle” rats subjected to 2 h occlusion 
followed by 3 days reperfusion. Melatonin significantly reduced the infarct volume in “MCAO  + Mel” 
(*p<0.05, n=10). Data are expressed as mm3 and represent mean  ± SEM. 
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3.1.5.2 Prevention of the loss of MAP-2 and NeuN staining in the ischemic tissue 
 
To elucidate at the cellular level, the extent to which neurons are protected in melatonin-
treated MCAO rats, we studied the changes in MAP-2 and NeuN immunoreactivity in the 
cortical infarct area. In the “Sham + Vehicle” rats, the MAP-2 staining was characterised 
by a uniform strong fluorescence of both dendrites and soma (Fig. 7A). After 24 h of 
reperfusion, a pronounced loss of MAP-2 staining (Fig. 7A) was observed in the “MCAO 
+ Vehicle” group, whereby some localised beaded pattern of immunoreactive structures 
remained. After melatonin treatment “MCAO + Mel”, the MAP-2 staining was preserved 
both, in the dendritic arbour and soma in the ischemic cortex of “MCAO + Mel” rats at 24 
h after reperfusion (Fig. 7A).  
 
A well defined NeuN staining was observed in “Sham + Vehicle” rats. In contrast, the 
NeuN-positive cells were almost completely lost from the ischemic cortex in “MCAO  + 
Vehicle” rats at 24 h after the start of reperfusion (Fig. 7A), indicating a massive neuronal 
degeneration. Melatonin treatment greatly prevented the loss of NeuN-positive cells after 
24 h of reperfusion in “MCAO + Mel” rats. 
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Fig 7A: MAP-2 and NeuN immunostaining: 
The upper panel of pictures shows MAP-2 immunostaining in sham-operated , vehicle- treated and 
melatonin-treated rats, subjected to 2 h occlusion followed by 24 h reperfusion. Neurons in “Sham + 
Vehicle” rats have an extensive array of branching dendrites and well defined somta stained for MAP-2.  
 
Sham + Vehicle MCAO + MelMCAO + Vehicle
MAP-2
NeuN
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A
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A loss of both, somatic and dendritic MAP-2 labelling is observed in “MCAO + Vehicle” rats at 24 h after 
reperfusion. Melatonin treatment prevented the loss of MAP-2 staining in “MCAO + Mel” rats. 
The lower panel shows NeuN immunostaining of sections from the same groups as shown in the upper panel. 
In “Sham + Vehicle” rats, a dense pattern of NeuN-positive cells is observed. In the “MCAO + Vehicle” rats, 
the NeuN-positive cells are almost completely lost at 24 h  after reperfusion. Melatonin preserved the NeuN-
positive cells in the ischemic tissue of the “MCAO + Mel ” group.       
 
Fig. 7B: Area of analysis:  
For microscopic analysis of the different antigens a location within the MCA-supplied cortex was chosen, 
that consistently showed lesions in the “MCAO + Vehicle” group and was seen to be recovered by drug 
treatments. Using landmarks such as the shape of the corpus callosum, the anterior commissure and the outer 
rim of the cortex,  this region was identified as the upper lip region of the somatosensory cortex in the 
coronal sections that were taken approx 0.2 mm anterior to bregma according to the Paxon and Watson Rat 
Brain stereotaxic atlas [151]. Therefore the observation field, as indicated by the location of the red box in 
the image, was placed within the coordinates 5-6 mm lateral to midline and 3-4 mm ventrally from the dorsal 
surface. The placement of the observation field was kept constant to enable comparisons of the 
immunofluorescence signals between the different treatment groups.  
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3.2 Oxyresveratrol (trans-2, 3’, 4, 5’-tetrahydroxystilbene) is neuroprotective and 
inhibits the apoptotic cell death in transient cerebral ischemia 
 
3.2.1 Physiological parameters 
 
Table I shows the summary of physiological parameters before and during ischemia. OXY 
treatment did not produce any change in the blood gases, pH, mean arterial blood pressure, 
blood glucose and hematocrit. 
 
Table 1: Physiological parameters for different treatment groups 
 
 15 min before ischemia 
 
 0 min of ischemia 30 min of ischemia 
Experimental 
Groups 
MCAO +        MCAO +
Vehicle            OXY 20    
         
MCAO +         MCAO + 
Vehicle            OXY 20         
MCAO +         MCAO + 
Vehicle            OXY 20         
pH 
 
7.4 ± 0.03 7.4 ± 0.03  7.2 ± 0.2 7.2 ± 0.03 7.3 ± 0.06 7.3 ± 0.03 
PCO2 (mm Hg) 
 
34.7 ± 6.1 37.4 ± 5.8 43.7 ± 4.1 42.7 ± 5.2 34.7 ± 6.1 38.7 ± 8.0 
PO2  (mm Hg) 208.3 ± 8.8 
 
217 ± 12.2 193.4 ± 10.8 
 
208 ± 6.1 208 ± 8.7 
 
198.3 ± 10.9 
HCT (%) 39.0 ± 0.6 
 
39.7 ± 0.7 40 ± 1.5 
 
40.7 ± 0.9 39.7 ± 1.2 
 
38.7 ± 0.03 
BGlu (mg/ml) 
 
8.9 ± 0.3 9.2 ± 0.5 8.9 ± 1.2 8.0 ± 1.1 9.1 ± 0.5 9.5 ± 0.5 
 
 
Hematocrit (Hct); blood glucose (BGlu); mean arterial blood pressure (MABP). 
All animals were maintained at 36.5± 0.5°C rectal temperature.  
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3.2.2 OXY treatment improved the neurological deficits in MCAO rats 
 
Evaluation by both method A and B showed no neurological deficits in “Sham + Vehicle” 
rats while in the animal-group “MCAO + Vehicle”, the neurological deficits were severe at 
24 h after reperfusion. The “MCAO + Vehicle” rats consistently showed circling 
movements and postural abnormalities besides other neurological signs like less to no 
spontaneous movements and severe paw flections. OXY treatment (10, 20 and 30 mg / kg 
dose) significantly (p < 0.05) improved the neurological outcome in “MCAO + OXY 10”, 
“MCAO + OXY 20” and “MCAO + OXY 30” rats as compared to the “MCAO + Vehicle” 
rats (Fig. 8). In “MCAO + OXY 10”, “MCAO + OXY 20” and “MCAO + OXY 30” 
animals, less disturbances in posture and no circling movements were observed when 
compared to the “MCAO + Vehicle” rats. There were no significant differences in the 
neurological deficits between the animals of “MCAO + OXY 10”, MCAO + OXY 20 and 
“MCAO + OXY 30” group (Fig. 8). In the SMA test (method B) the rats in the “MCAO + 
Vehicle” group spend most of the time in the center of the cage with posture curved 
towards the paretic side while “MCAO + OXY 10”, MCAO + OXY 20 and “MCAO + 
OXY 30” rats moved around in the cage and explored their environment. By increasing the 
dose to 30 mg / kg, no further neuroprotection was seen. There were no significant 
differences in the neurological scoring between OXY-treated (2, 10, 20 and 30 mg dose) 
and vehicle-treated sham-operated rats. (data shown for 20 mg dose only).  
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Fig. 8: OXY treatment improved the neurological function in MCAO rats: 
Neurological deficits in rats that were subjected to MCAO, measured by scoring methods A and B. “MCAO 
+ Vehicle” rats showed severe neurological deficits 24 after occlusion as compared to “Sham + Vehicle” rats. 
10, 20 or 30 but not 2 kg OXY i.p. improved the neurological status significantly (p < 0.05). There was no 
further improvement in the neurological deficits with 30 mg. Data represents mean ± SEM for each group (n 
=10).  
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3.2.3 OXY reduced the infarct volume in MCAO rats 
 
TTC staining of brain sections obtained from “Vehicle + MCAO” rats showed 
reproducible and readily detectable lesions in the areas that are supplied by the MCA at 3 
days after the reperfusion (Fig. 9 A). The lesions were present in both the lateral striatum 
and the overlying cortex. OXY (10 or 20 mg / kg i.p.) reduced significantly the infarct 
volume to 166.2 ± 12.5 mm3 and 145.0 ± 11.5 (p < 0.05, n = 8) respectively, as compared 
to the “MCAO + Vehicle” group (261.0 ± 18.5 mm3, n = 8, Fig. 9 B). There was no 
significant difference in the infarct volume between vehicle treated and OXY 2 treated 
MCAO rats (“MCAO + Vehicle” and “MCAO + OXY 2”, respectively). By increasing the 
dose to 30 mg / kg, no further protection was seen. 
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Fig. 9: OXY reduces the infarct volume: 
A. TTC-stained coronal sections from representative MCAO-subjected animals that received either vehicle or 
OXY (10 or 20 mg / kg i.p.) at the time of occlusion and at reperfusion (euthanised 3 days after the 
experiment). The infarcts, observed as pale regions, are considerably smaller in OXY treated rats when 
compared to the vehicle-treated animal. 
 
B. Statistical analysis of infarct volume: 
Infarct volumes were significantly (*p < 0.05) reduced after OXY 20 and Oxy 10 treatment in MCAO rats. 
There was no significant difference in the infarct volume between OXY 2 and vehicle treated MCAO rats. 
Data are expressed as mm3 and represents mean ± SEM (n = 8 in each group). 
 
  
3.2.4 Histological analysis 
 
Since the 20 mg / kg dose was maximal effective in improving the neurological deficits 
and in reducing the infarct volume, we used this dose for further evaluation of effects on 
the apoptotic cascade and for assessing the markers of neuronal degeneration, using 
immunohistochemical techniques. Microscopic analysis was carried out in the region 
specified in Fig. 7 B.  
 
3.2.4.1 MAP-2 and NeuN staining in the ischemic tissue 
 
To assess the extent to which neurons are protected in OXY-treated MCAO rats, we 
studied the changes in MAP-2 and NeuN immunoreactivity in the ischemic cortical area, 
depicted in Fig. 7 B. In “Sham + Vehicle” group, the MAP-2 staining was characterized by 
a uniform strong fluorescence of both dendrites and soma (Fig. 10) indicating intact 
neurons. After 24 h of reperfusion, a pronounced loss of MAP-2 staining (Fig. 10) was 
observed in the “MCAO + Vehicle” animals, whereby some localized beaded patterns of 
immunoreactive structures remained. After OXY treatment in “MCAO + OXY 20” rats, 
the MAP-2 staining was preserved both in the dendritic arbour and the somata of the 
neurons in the ischemic cortex 24 h after reperfusion (Fig. 10).  
 
A well-defined NeuN staining was observed in “Sham + Vehicle” rats (Fig. 10). In 
contrast, the NeuN-positive cells were almost completely lost from the ischemic cortex in 
“MCAO + Vehicle” group at 24 h of reperfusion (Fig. 10), indicating a massive neuronal 
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degeneration. OXY treatment prevented the loss of NeuN-positive cells after 24 h of 
reperfusion in “MCAO + OXY 20” rats. 
 
 
 
 
 
 
Fig. 10: MAP-2 and NeuN immunostaining: 
The upper panel of pictures shows MAP-2 immunostaining in coronal brain sections of  different 
experimental groups. Typical neuronal structures with an extensive array of branching dendrites and well 
defined somata are seen in “Sham + Vehicle”. A loss of both somatic and dendritic MAP-2 labeling is 
observed in “MCAO + Vehicle” rats at 24 h after reperfusion. OXY treatment prevented largely the loss of 
MAP-2 staining. 
The lower panel shows NeuN immunostaining of sections from the same animals as shown in the upper 
panel. In “Sham + Vehicle” rats, a dense pattern of NeuN-positive cells is observed. In the “MCAO + 
Vehicle” rats, NeuN-positive cells are almost completely lost at 24 h after reperfusion. OXY treatment 
prevented the loss of NeuN-positive cells.  
 
 
 
MCAO + OXY 20 Sham + Vehicle MCAO + Vehicle 
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3.2.4.2 OXY prevented cyt c release from mitochondria 
 
MCAO followed by reperfusion in the “MCAO + Vehicle” group caused a pronounced 
increase in cytosolic cyt c immunoreactivity 4 h as well as 24 h after the reperfusion (Fig. 
11 A). At 4 h, the cytosol was strongly stained for cyt c immunoreactivity. 24 h after 
reperfusion, cyt c immunoreactivity was additionally detected in the extracellular spaces 
(Fig. 15 A), whereas “Sham + Vehicle” rats showed a cyt c staining pattern at both 4 h as 
well as 24 h (Fig. 11 A) that was indicative of intact mitochondria. When MCAO-
subjected animals were treated with OXY “MCAO + OXY 20”, the cytosolic cyt c 
immunostaining as well as the extracellular cyt c staining signals decreased both at 4 h and 
24 h (Fig. 11 A) as compared to “MCAO + Vehicle” animals.  
 
3.2.4.3 OXY prevented caspase-3 activation 
 
At 4 h of reperfusion, sections of “MCAO + Vehicle” animals showed a strong 
immunoreactivity for caspase-3 in the ischemic cortex as compared to the “Sham + 
Vehicle” group (Fig. 11 B). An increased caspase-3 immunoreactivity was still detectable 
at 24 h after reperfusion, however, the caspase-3 immunoreactivity was not only localised 
in well defined cellular compartments (Fig. 11 B) but was also in cell debris. Upon OXY 
treatment, the caspase-3 activation was strongly reduced in “MCAO + OXY 20” rats at 
both the investigated-time points (Fig. 11 B). No changes in caspase-3 staining were 
observed in “Sham + OXY 20” rats when compared to “Sham + Vehicle” rats. 
 
3.2.4.4 OXY reduced apoptotic DNA fragmentation 
 
In “MCAO + Vehicle” rats, the Apostain-label was observed in the nuclei of a large 
number of cells. Such Apostain-positive cells showed a characteristic morphology of 
apoptotic cells with shrunken structures. The number of Apostain-positive cells was 
reduced in the OXY-treated MCAO “MCAO + OXY 20” rats (Fig11 C) showing an anti-
apoptotic effect of OXY. 
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Fig. 11: OXY treatment inhibited the apoptotic cell death in MCAO rats: 
A. Cytosolic cyt c immunoreactivity is decreased in MCAO brain tissue upon OXY treatment: 
Representative images of cyt c immunostaining in the MCA-supplied cortex (for location, see Fig. 7B), 
obtained at 4 h (upper panel) or 24 h (lower panel) after reperfusion. No specific cytosolic immunostaining is 
seen in the “Sham + Vehicle” rats at 4 h and 24 h. Characteristic cyt c labeling in the cytosol of cells is 
observed at 4 h and 24 h in “MCAO + Vehicle” rats. 24 h later, the staining is also present in the intercellular 
space indicating the presence of cell debris. OXY 20 treatment reduces the cytosolic cyt c immunostaining in 
“MCAO + OXY 20” rats both at 4 h and 24 h after reperfusion. Inserts are showing the magnified views of 
selective cyt c positive neurons.  
 
B. MCAO-induced caspase-3 immunoreactivity is reduced by OXY:  
Caspase-3 immunofluorescence of the MCA-supplied cortex in the sections adjacent to those seen in A. No 
activation of caspase-3 is seen in “Sham + Vehicle” rats while in “MCAO + Vehicle” rats, most of the cells 
show an increased caspase-3 immunostaining at 4 h and 24 h after reperfusion. OXY treatment decreased the 
caspase-3 activation both at 4 h and 24 h after ischemia in “MCAO + Oxy 20” rats. 
 
C. OXY protects against MCAO-induced DNA fragmentation: 
Images of Apostain-labeled cortices, indicating the presence of apoptotic ssDNA. In “Sham + Vehicle” rats, 
no staining is observed while in the “MCAO + Vehicle” rats most of the cells are Apostain positive. The 
darkly stained cells are shrunken and have a characteristic apoptotic-like appearance. OXY treatment 
decreased the number of Apostain-positive cells in “MCAO + OXY 20” rats. 
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4 .  D I S C U S S I O N  
 
4.1 Direct inhibition of mtPTP by melatonin and its anti-apoptotic effects in cerebral 
ischemia 
 
We were prompted to consider an action of melatonin on the mtPTP pathway by the initial 
observation that melatonin decreased the NMDA-induced sustained [Ca2+]c plateaus. Such 
elevated [Ca2+]c during continuous NMDA application is a result of Ca2+ influx and 
internal trafficking of the Ca2+ load whereby endoplasmic and mitochondrial Ca2+ uptake 
as well as Ca2+ release from these sites plays a role. The mitochondria act as Ca2+ buffers 
by sequestering excess Ca2+ from the cytosol. The [Ca2+]c continues to rise when NMDA 
receptors are continuously stimulated causing Ca2+ uptake into the mitochondria that upon 
reaching a threshold level leads to mtPTP opening, which in turn produces Ca2+-induced 
Ca2+ release [152]. The mitochondrial permeability transition, allowing the non-selective 
permeation of ions and solutes through the mitochondrial membrane, is CsA sensitive 
[105, 153]. Indeed, our experiments, using CsA at a low concentration that is primarily 
known to block the mtPTP [152], lowered the NMDA-induced [Ca2+]c levels. This effect 
indicates the presence of a mtPTP-mediated Ca2+ release that contributes to the overall 
[Ca2+]c level in our cell culture model. 
 Melatonin, when used analogous to the CsA treatment, showed in our experiments an 
almost identical pattern in reducing the NMDA-induced [Ca2+]c levels as seen with CsA. 
Such observation would indicate either a direct effect of melatonin on the mtPTP or on 
mechanisms upstream of mtPTP activation. One of such upstream factors is excessive free 
radical levels that may also lead to an mtPTP induction. Indeed, we showed earlier that the 
NMDA-induced [Ca2+]c rises possess a component that is due to mtPTP activation by NO 
[146]. Taking in account that melatonin is an excellent radical scavenger and antioxidant 
[116] one would assume that the observed effect on [Ca2+]c after NMDA is due to the 
removal of NO or other reactive oxygen species that are believed to lead to the 
pathological mtPTP formation [154]. 
However, we show here that another mechanism, the observed direct inhibition of the 
mtPTP, is likely to contribute also to this effect.  The mtPTP patches obtained from 
mitoplasts, derived from liver mitochondria showed the characteristic voltage dependence 
and large conductance of more than 1 nS [147]. The observed blockade of mtPTP currents 
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by CsA application to the mitochondrial membrane patches together with the earlier shown 
Ca2+-dependence indicate that the investigated megachannel was indeed the mtPTP. 
Comparability of mtPTP behavior in mitoplasts with observations made using O2-
measurements or a swelling assay (published as an abstract, Siemen et al., 2002, 
Restorative Neurology and Neuroscience 20:275-276) make it unlikely that the osmotic 
shock could have unpredictably altered the behaviour of the mtPTP. As the patches were 
prepared at high Ca2+ concentration mostly fully open mtPTPs were detected at the time of 
experiment. This comprises an advantage for the patch clamp technique because 
potentially mtPTP-modulating factors like free radicals, which are effective upstream of 
the direct interactions with the channel, are excluded. Hence, the observed dose-dependent 
reduction in the pore currents due to bath application of melatonin is solely due to a direct 
interaction of melatonin with the channel. Our data show that the efficacy of melatonin in 
inhibiting the mtPTP is high with an IC50 of 0.8 µM. The inhibitory effect started quickly 
at 10 s after the addition of melatonin to the patch-clamp bath solution and the effect was 
seen even at very low concentrations (200 nM). In the light of the well known reducing 
capacity of melatonin one could speculate that a direct action on the mtPTP is possibly a 
common feature of antioxidants. However, preliminary results in our laboratory using the 
polyphenolic hydroxystilbene oxyresveratrol show that this antioxidant [155] failed to 
block mtPTP currents. 
Previous studies using various other mtPTP blocking agents show that in pathological 
conditions such as ischemia, an excessive loading of Ca2+ into the mitochondria induces 
apoptosis by stimulating the release of apoptosis-promoting factors like cyt c, AIF, 
Smac/DiaBLO and procaspases from the mitochondrial intermembrane space into the 
cytoplasm via a permeability transition mechanisms [40]. The release mechanisms is 
believed to be accompanied by mitochondrial depolarisation that follows the mitochondrial 
permeability transition. Hence, one would assume that melatonin, being an mtPTP blocker, 
may preserve ∆Ψm in ischemic conditions. To test this assumption, we used an OGD 
model of neuronal cultures in conjunction with live cell imaging of the fluorescent dye 
TMRM that is selectively taken up in energized mitochondria. As expected, we found that 
the TMRM uptake in OGD-subjected cultures was strongly compromised compared to 
control cultures indicating that the noxious OGD stimulus leads to a decrease in ∆ψm as  
previously reported [156]. The protection against the OGD-induced loss of TMRM-uptake 
by CsA in our OGD model indicates the involvement of the mtPTP in the mitochondrial 
depolarisation. Indeed, melatonin also prevented the loss in TMRM uptake, which in turn 
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reflects the preservation of ∆ψm. The TMRM uptake was not altered by melatonin in 
control cultures that were not subjected to OGD, indicating that melatonin exerts its effect 
only when pathological conditions like mtPTP formation prevail. It has been shown that 
CsA in addition to its effect on the mtPTP has the potential to inhibit also the multi drug 
resistance pump (MDR). This may cause changes in attaining the mitochondrial TMRM 
fluorescence in the cells that is independent of mtPTP action (for review, see [60]). 
Previously it was shown that the MDR inhibition by verapamil, that is also an MDR 
inhibitor, did not cause any alteration in the CsA-induced mitochondrial hyperpolarization 
[157]. If the component of MDR inhibition plays a role in our experimental model, one 
would assume that a treatment with verapamil results in a higher mitochondrial TMRM-
uptake. Our results show that MDR inhibition by verapamil did not produce any change in 
attaining the mitochondrial TMRM-uptake. Furthermore, using different concentrations 
(50-200 nM, concentrations that are below the self-quenching threshold) of TMRM, 
showed no changes in mitochondrial fluorescence (data not shown), indicating, that an 
increased intracellular availability of TMRM as it would result from a MDR blockade, 
does not alter the baseline fluorescence in our model. Thus, our results show that a possible 
MDR inhibition in our model does not affect the mitochondrial TMRM uptake using our 
loading protocol. A large body of evidence suggests that the mtPTP is causally involved in 
the pathological changes following ischemia/reperfusion [59, 158]. Hence, a blockade of 
the mtPTP by melatonin may comprise a pharmacological strategy for the treatment of 
such pathological conditions.  
During ischemia, the ATP level drops and the concentration of ADP and AMP increase 
due to the cessation of the mitochondrial oxidative phosphorylation [159]. Furthermore, 
tissue acidosis occurs during ischemia due to lactate accumulation [160]. Adenine 
nucleotides and low pH are potent blockers of the mtPTP [109], therefore it is unlikely that 
mtPTP opening occurs during the occlusion phase of stroke. Also, the uptake of cytosolic 
Ca2+ into mitochondria, being a pre-requisite for mtPTP formation is prevented by the 
mitochondrial depolarization that is initiated soon after the onset of the occlusion. 
However, during reperfusion, mitochondria become re-energized, hence the sequestration 
of Ca2+ that gets accumulated in the cytosol during ischemia [161] is reinstated. In 
addition, a shift towards a higher pH and excessive free radical generation has to be 
expected under such conditions [61, 62]. All these factors that occur during reperfusion 
favour the mtPTP formation. Accordingly, mitochondrial swelling as a result of 
permeability transition is observed in neurons within the first hours of reperfusion [162]. 
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Taking into consideration that the reperfusion phase after ischemia is essential for the 
mtPTP opening, we choose to examine the effect of melatonin on the pathological changes 
in an MCAO model with 2 h occlusion followed by reperfusion. mtPTP-mediated brain 
injury has already been characterized in this MCAO model [163] and it was shown before 
that CsA treatment is protective in similar models of brain ischemia [111, 113]. Since CsA 
also inhibits calcineurin, one could assume that CsA may act as a protectant at least in part 
by utilizing this pathway. In most of these studies the neuroprotective effect of CsA was 
observed to be much more efficacious than that of FK506, an immunosuppressant that has 
an ability to inhibit calcineurin like CsA but has no effect of mtPTP. Moreover, N-methyl-
valine-4-cyclosporine A (MeValCsA), a CsA analogue that has no effect on calcineurin, 
but blocks the mtPTP opening, has been shown to decrease the infarct volume in the 
MCAO model to the same extent as seen with CsA [164].  
We used cyt c immunoreactivity in the cytosol as a marker for mtPTP activation in our 
MCAO model. It was shown before that such ischemia-induced cyt c release is blocked by 
CsA [165] indicating a mtPTP-dependent mechanism. Consistently we also observed high 
levels of cyt c immunoreactivity in the brain cytosol of MCAO-subjected rats at 4 h as well 
as at 24 h after the onset of reperfusion. We then proved our hypothesis that melatonin 
treatment reduces this increase in cytosolic cyt c immunoreactivity too, suggesting a lower 
mtPTP activity in presence of the drug. Such mtPTP-mediated cyt c release appears to be a 
feature also of other neuropathologies: CsA reduced the cyt c release from mitochondria in 
kainate-induced excitotoxicity in organotypic hippocampal cultures [166] and in neurons 
exposed to transient hypoglycemia [167]. Isolated brain mitochondria were shown to 
release cyt c in a mtPTP dependent mechanism when subjected to high Zn2+ levels [168] or 
to the neurotoxin MPP+, used in experimental  Parkinson models [169].  
Some contradicting studies on isolated mitochondria suggest that the release of cyt c might 
occur also independently of the mtPTP. For example, Andreyev and Fiskum [42] showed 
that mtPTP-mediated cyt c release was found in liver but not in brain mitochondria 
suspensions. The discrepancy between these studies is not fully understood. It was 
suggested that the induction of mtPTP opening and subsequent cyt c release from brain 
mitochondria might require the intact tissue [42]. 
We followed the cascade of events that extends downstream from the mtPTP-mediated cyt 
c release by examining how melatonin affects the caspase-3 activation [167] and the 
subsequent DNA fragmentation [170]. Our MCAO model displayed an activation of 
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caspase-3 that was inhibited by melatonin consequentially also prevented the DNA 
fragmentation.  
The melatonin-induced anti-apoptotic effects presented here are in agreement with other 
studies showing that melatonin inhibits apoptosis in ischemic kidney [171], in amyloid 
beta-peptide injury in hippocampal neurons [172] and NO-induced cell death in PGT-beta 
immortalized pineal cells [173]. It is interesting to note that melatonin is not protective in 
all models of apoptotic cell death [174], which may find its explanation in the fact that all 
the investigated noxious stimuli do not trigger mtPTP mediated apoptotic pathways. For 
example, melatonin does not protect against staurosporine-induced apoptosis, which is 
known to follow pathways that do not involve mitochondrial depolarization, hence the 
mtPTP is unlikely to be involved [175, 176]. 
 Our in-vivo data do not rule out additionally to the direct mtPTP inhibition, an indirect 
effect of melatonin on the mtPTP activation by removing reactive nitrogen or oxygen 
species from the tissue. The clearly observed in-vitro actions of melatonin directly on the 
mtPTP may rather contribute to the overall outcome of its protective effect in in-vivo 
stroke models. The finding of a reduction in the infarct volume in our studies, is in 
agreement with  previous results obtained by different authors that melatonin reduces the 
infarct size after cerebral ischemia [117-120] and serves here as a control for effectiveness 
of the MCAO insult. 
 The dose used in the present study is a pharmacological dose that has already been shown 
to cause neuroprotection in different models of neuronal degeneration [119, 177, 178]. The 
relevance of physiological melatonin levels in inhibiting brain damage due to ischemia / 
reperfusion in rats was confirmed by Kilic et al [179]. They showed that physiological 
melatonin concentrations are neuroprotective and also the pharmacological application 
effectively reduces the brain damage and improves the neurological status of ischemic rats. 
The findings that physiological melatonin concentrations are neuroprotective is of 
particular interest since endogenous levels of melatonin are diminished in many aged 
individuals; [180]. Thus, elderly individuals may be increasingly vulnerable to the 
damaging effects of a stroke because they lack the endogenous protectant melatonin. 
Melatonin is well known to modulate the activities of hypothalamic centers that regulate 
the circadian rhythm. Diurnal modulations of Ca2+ currents in the suprachiasmatic nucleus 
of the hypothalamus is reported to transduce the intracellular cycling of molecular clocks 
and circadian rhythm [181]. Since the mtPTP at its low-conductance state  plays a role in 
the regulation of cellular Ca2+  homeostasis [152] one may speculate in the context of our 
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findings that melatonin could modulate such pathways. The results of the present study 
therefore open a new field for investigating other regulatory principles  in melatonin 
controlled mechanisms. Taken together, our results demonstrate for the first time that 
melatonin directly inhibits the mtPTP and that this effect may contribute to the anti-
apoptotic properties of melatonin. The direct inhibition of mtPTP provides an evidence for 
an alternative mechanism that is utilized by melatonin to offer neuroprotection. Being an 
antioxidant and inhibitor of the mtPTP, therapeutic intervention by melatonin may provide 
a beneficial clinical applications for the treatment of stroke and neurodegenerative 
disorders.  
Melatonin, being safe and non-toxic, more experimental studies should be conducted to 
explore the synergetic actions of melatonin with other drugs, presently applied clinically.  
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4.2 OXY protects the neurons and inhibits apoptotic cell death in transient brain 
ischemia 
 
In this study we provide evidence that OXY is a potent neuroprotectant in transient brain 
ischemia. In many clinical cases of stroke, reperfusion occurs after the occlusion phase 
spontaneously or is induced by pharmacological thrombolysis. Hence our MCAO model 
with a defined ischemic period and subsequent reperfusion resembles many features of the 
clinical situation in stroke patients [142, 182]. Moreover, middle cerebral artery, the 
specific occlusion site in this model, is the most commonly affected vessel in both embolic 
or thrombotic strokes in humans [3].  
Here we show that an intraperitoneal application of a dose of 10 mg / kg OXY is sufficient 
to provide significant neuroprotection against MCAO-induced neuronal injury. This 
finding was supported by both histological and neurological data: we observed a reduction 
in the brain infarct volume after the ischemic insult and an attenuation of the neurological 
deficits, which are clinical features that are related to the life quality after stroke. OXY 
treatment reached, in our hands, a maximal protective capacity at a dose of 20 mg / kg, 
since no further neuroprotection was seen by increasing the dose to 30 mg / kg. A low dose 
of 2 mg / kg was not protective. To exclude indirect protective effects of OXY, for instance 
via alteration of the general physiological homeostasis like changes in blood pressure, 
body temperature or blood gas levels, which are known to affect the outcome of an 
ischemic insult [183, 184], we took great care to maintain these parameters at a constant 
level. Hence, the observed neuroprotection by OXY is apparently not attributed to such 
side effects. 
 We showed earlier in in-vitro studies that OXY is a potent antioxidant and scavenges ROS 
/ RNS [131]. These findings include detoxifying effects for NO, H2O2 and O2.- [131, 185], 
species that are known to display strongly increased levels in the ischemic and post-
ischemic brain [54-56]. It is commonly accepted that thereby induced oxidative / 
nitrosative stress plays a crucial role in the brain injury after ischemia / reperfusion (for 
review, see [54-56]). For example, activated microglial cells are identified as a source of 
elevated NO levels and other potentially pro-apoptotic factors in neuronal degeneration 
[139, 186-188]. In this context it is interesting to note that OXY inhibits LPS- and 
interferon-γ-induced microglial / macrophage activation and NO-output [131, 189]. 
Moreover, OXY was shown to remove such highly activated microglial cells from LPS- 
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and interferon-γ-treated primary mixed neuronal-glial mouse cultures that in turn 
contributes also to lower ROS / RNS levels. The neuroprotective effects by OXY may be 
explained by a combined effect of both, its antioxidative / antinitrosative actions and the 
decrease in ROS / RNS-producing microglial cell numbers. 
Mitochondria are the cellular site that are prone to potentially harmful oxidative damage 
[190]. Such mitochondrial injury is reported to cause cyt c release into the cytosol that 
initiates the apoptotic cell death cascade [191]. OXY being a potent antioxidant, should 
interrupt this chain of events upstream of the mitochondrial damage by diminishing ROS / 
RNS concentrations. Here we used the cytosolic cyt c level as a marker to assess the 
effectiveness of cytoprotective action of OXY. Our results demonstrate that cyt c is 
released from the mitochondria into the cytosol within 4 h after reperfusion, indicating that 
ischemia / reperfusion may trigger mitochondrially-induced apoptosis, possibly by 
increasing the permeability of the mitochondrial membranes. At 24 h of reperfusion, cyt c 
was also seen extracellularly, showing that the cells get disrupted, whereby the contents 
including cyt c are shed-off into the extracellular space. In sham-operated rats, a low 
intensity - punctate pattern of the cyt c immunoreactivity, taken as an indicator of intact 
mitochondria, was observed. However, once released from the mitochondria, the cyt c 
signal is readily detectable. The reason for the low cyt-c immunofluorescence signal in 
intact mitochondria is partly attributed to the fixation procedure (as in our case with 4 % 
PFA) that hinders the antibody to reach the intermembrane space of mitochondria [192]. 
Another possible explanations are, that  cyt c is densely packed into the intermembrane 
space that results in the commonly known phenomenon of collissional quenching  of  the 
fluorescence because the dye molecules reach a very high local concentration after the 
immunoreaction or that steric hinderance prevents the antibody from reaching the antigen.  
Also, once released into the cytosol, conformational changes occur in the cyt c molecule 
that leads to increased antibody binding to the protein [193] and in turn to a higher 
fluorescence signal. In any case, the strong cytosolic cyt c immunofluorescence is a 
suitable measure for mitochondrially released cyt c.  OXY treatment in MCAO rats not 
only reduced such cytosolic cyt c staining at 4 h, but also decreased the extracellular label 
at 24 h, indicating a reduction of damage to the mitochondria. Along the line that cyt c 
release from mitochondria after ischemia / reperfusion activates the pro-apoptotic caspase-
3 [51-53] , we show that MCAO-induced apoptosis was decreased by OXY treatment. 
Accordingly, immunohistochemical staining for caspase-3 as well as labeling of apoptotic-
DNA was also found to be reduced after OXY treatment. Prevention of apoptotic cell death 
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by antioxidant application is in agreement with other studies [171, 194]. An increase in the 
expression of the endogenous antioxidant enzyme Cu / Zn-superoxide dismutase in rats 
yielded similar results by limiting cyt c release and caspase-3 activation and, thus, 
preventing subsequent apoptotic cell death in models of cerebral ischemia [192].  
Taken together, we expanded on our previous in-vitro data [131] by demonstrating that 
OXY is also a potent neuroprotectant in an in-vivo model of stroke. From the results of the 
present study, we suggest that OXY may prove an excellent drug for the treatment of 
neurodegenerative disorders that causally involve oxidative / nitrosative stress, especially 
in stroke.  
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5 .  S U M M A R Y  A N D  C O N C L U S I O N  
 
Focal brain ischemia caused by reduced supply of blood to cerebral tissue, results in 
cellular damage within the first few hours up to weeks after the insult. Extensive loss of 
neurons as well as glia in such ischemic brain areas is the characteristic pathological 
feature of cerebral infarcts causing mild to severe neurological symptoms that may even 
lead to the death of the subject. The cascade of events in the pathogenesis of stroke 
involves oxidative and nitrosative stress, i.e., the deleterious effects of reactive oxygen and 
nitrogen species (ROS / RNS). 
It is known that RNS / ROS cause mitochondrial damage and lead to an accumulation of 
pro-apoptotic high cytosolic Ca2+ ([Ca2+]c) in the cells. It is now realised that an activation 
of the mitochondrial permeability transition pore (mtPTP), a megachannel formed in the 
mitochondrial membranes contributes to such pro-apoptotic [Ca2+]c rise. Also, the mtPTP 
opening leads to the release of pro-apoptotic proteins like cytochrome c (cyt c), apoptosis 
inducing factor (AIF), Smac / DiaBLO and procaspases from the mitochondrial 
intermembrane space into the cytoplasm. The release of cyt c into the cytosol initiates the 
cascade of mitochondrial apoptotic cell death by activating caspase-3. 
Treatment with drugs that can either directly inhibit the mtPTP or can reduced the 
oxidative / nitrosative stress are therefore potential pharmacological interventions to reduce 
the ischemia- induced brain injury.  
 
5.1 Melatonin, the secretory product of the pineal gland, is known to be neuroprotective in 
cerebral ischemia, which is so far mostly attributed to its antioxidant properties. Here we 
show that melatonin directly inhibits the mtPTP. Consistently, NMDA-induced [Ca2+]c 
rises were diminished by melatonin in cultured mouse striatal neurons, similar to the 
pattern seen with cyclosporine A (CsA), an inhibitor of mtPTP. When the mouse striatal 
neurons were subjected to oxygen-glucose deprivation (OGD), melatonin strongly 
prevented the OGD-induced loss of mitochondrial membrane potential. To assess the direct 
effect of melatonin on the mtPTP activity at the single channel level, recordings from the 
inner mitochondrial membrane were obtained by a patch-clamp approach using rat liver 
mitoplasts. Melatonin strongly inhibited mtPTP currents in a dose-dependent manner with 
an IC50 of 0.8 µM. If melatonin is an inhibitor of the mtPTP, it should prevent 
mitochondrial cyt c release as seen in stroke models. Rats underwent middle cerebral artery 
SUMMARY AND CONCLUSION 61
occlusion (MCAO) for 2 h followed by reperfusion. Melatonin (10 mg/kg intrapertoneal, 
i.p.) or vehicle was given at the time of occlusion and at the time of reperfusion. Indeed, 
infarct area in the brain sections of melatonin-treated animals displayed a considerably 
decreased cyt c release along with less activation of caspase-3 and apoptotic DNA 
fragmentation. Melatonin treatment diminished the loss of neurons and decreased the 
infarct volume as compared to vehicle-treated MCAO rats. Our findings suggest that the 
direct inhibition of the mtPTP by melatonin may essentially contribute to its anti-apoptotic 
effects in transient brain ischemia. 
 
5.2 Since oxidative / nitrosative stress is one of the major pathological factors in the 
cascade of cell death in cerebral ischemia, we investigated the neuroprotective effect of a 
naturally occurring antioxidant, oxyresveratrol (OXY) to reduce brain injury after cerebral 
stroke. We used the MCAO model of transient brain ischemia to induce a defined brain 
infarction. OXY was given twice i.p.: immediately after occlusion and at the time of 
reperfusion. OXY (10 or 20 mg / kg) significantly reduced the brain infarct volume by 
approximately 54  ± 4 % and 63 ± 5 %, respectively, when compared to vehicle-treated 
MCAO rats. Also, the neurological deficits as assessed by different scoring methods 
reduced in OXY-treated MCAO rats. Histological analysis of apoptotic markers in the 
ischemic brain area revealed that OXY treatment diminished cyt c release from the 
mitochondria and decreased caspase-3 activation in MCAO rats. Also, staining for 
apoptotic DNA showed that the number of apoptotic nuclei in ischemic brain were reduced 
after OXY treatment as compared to the vehicle-treated MCAO rats. These  findings 
demonstrate that OXY is neuroprotective in an in-vivo stroke model by limiting ischemia-
induced brain injury.  
Taken together, we show here for the first time that the endogenous pineal hormone 
melatonin is a blocker of the mtPTP. Our data indicate that this property of melatonin 
contributes to its neuroprotective effects both, in-vitro and in-vivo. 
Furthermore, we established the naturally occurring hydroxystilbene, OXY as a potent 
neuroprotectant in a transient brain ischemia model, by demonstrating strongly reduced 
infarct volumes and neurological deficits upon its treatment after stroke insults.  
Our data show that both melatonin and OXY are potential drugs for the development of 
pharmacological intervention in stroke therapy.  
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6 .  Z U S A M M E N F A S S U N G  
 
Eine fokale Ischämie des Zentralnervensystems wird durch die reduzierte Blutversorgung 
eines distinkten cerebralen Hirnareals verursacht. Das führt zu massiven Zellschädigungen 
innerhalb der ersten Stunden bis zu Wochen nach dem Insult. Der extensive Verlust von 
Neuronen und Gliazellen in einem von Ischämie betroffenen Areal ist das pathologische 
Hauptcharakteristikum eines Schlaganfalls und führt - je nach Ausmaß und Lokalisation - 
zu neurologischen Symptomen verschiedener Schweregrade bis hin zum Tode des 
Patienten. In der Ereigniskaskade der Pathogenese des Schlaganfalls spielt oxidativer und 
nitrosativer Stress eine wichtige Rolle, hervorgerufen durch die schädigenden Effekte von 
reaktiven Stickstoff- und Sauerstoffspezies (ROS/RNS). Es ist bekannt, dass RNS/ROS 
einen direkt schädigenden Einfluß auf Mitochondrien ausüben und zu einer potentiell 
proapoptotischen Akkumulation von Ca2+ im Zytosol ([Ca2+]c) führen können. Zu diesem 
proapoptotische Anstieg des [Ca2+]c trägt wahrscheinlich die Aktivierung der 
mitochondrialen permeability transition pore (mtPTP) bei, einem Megakanal, der sich 
durch die innere und äußere Membran der Mitochondrien spannt. Durch die mtPTP können 
auch proapoptotische Proteine, wie Cytochrom C (cyt c), apoptosis inducing factor (AIF), 
Smac/DiaBLO und Procaspasen, aus dem Intermembranraum in das Zytosol gelangen. Die 
Freisetzung von cyt c in das Zytosol initiiert die mitochondriale apoptotische 
Zelltodkaskade über eine Aktivierung von Caspase-3. Die Behandlung cerebraler Ischämie 
mit Substanzen, die entweder die mtPTP direkt inhibieren oder die den 
oxidativen/nitrosativen Stress reduzieren, erscheint von besonderem Interesse, weil von 
einer solchen pharmakologischen Intervention zur Reduzierung der durch Ischämie-
verursachten Hirnschädigung eine entsprechende Wirksamkeit erwartet werden kann.  
Die der Dissertation zugrunde liegenden  Untersuchungen konzentrieren sich zunächst auf 
Melatonin. Melatonin ist ein Amin, das von Zellen des Pinealorgans synthetisiert und 
sezerniert wird. Es wird als Neuroprotektivum im Zusammenhang mit cerebraler Ischämie 
diskutiert, wobei die Wirkung hauptsächlich seinen antioxidativen Eigenschaften 
zugeschrieben wird. Hier wird erstmalig gezeigt, dass Melatonin die mtPTP direkt 
inhibieren kann. Übereinstimmend damit belegen die weiteren Ergebnisse, dass der 
NMDA-induzierte [Ca2+]c-Anstieg in striatalen Maus-Neuronenkulturen durch Melatonin 
reduziert wird, ähnlich der Wirkung, die man bei Behandlung mit Cyclosporin A (CsA), 
einem Blocker der mtPTP, beobachtet. Wenn solche Neuronenkulturen einem Sauerstoff-
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Glukose-Entzug (OGD) ausgesetzt wurden, dann war Melatonin in der Lage, den durch 
OGD verursachten Verlust des mitochondrialen Membranpotentials zu verhindern. Um den 
direkten Effekt von Melatonin auf die mtPTP-Aktivität auf Einzelkanalebene zu ermitteln, 
wurde in elektrophysiologischen patch-clamp Studien die mtPTP-Aktivität an der inneren 
mitochondrialen Membran von Lebermitoplasten aufgezeichnet. Dabei zeigte sich, dass 
Melatonin dosisabhängig die mtPTP-Ströme mit einem IC50 von 0,8 µM inhibiert. 
Auf der Basis dieser Ergebnisse kann vermutet werden, dass Melatonin als wirksamer 
mtPTP-Blocker die Freisetzung von cyt c aus Mitochondrien in das Zytosol, analog zu der 
des Ca2+, verhindert. Für eine entsprechende Untersuchung am Ganztier benutzten wir das 
middle cerebral artery occlusion (MCAO)-Modell, bei dem in Ratten die Arteria media 
cerebri für zwei Stunden mit nachfolgender Reperfusion okkludiert wird. Melatonin (10 
mg/kg, i. p.) oder die entsprechende Vehikel-Lösung wurden wiederholt appliziert: einmal 
nach der Okklusion und einmal zum Zeitpunkt der Reperfusion. Tatsächlich zeigte das 
Infarktareal in Hirnschnitten von Melatonin-behandelten Tieren eine stark verringerte cyt 
c- Immunoreaktivität im Zytosol, begleitet von einer reduzierten Aktivierung von Caspase 
3 und apoptotischer DNA-Fragmentierung. Melatonin verringerte auch den Verlust von 
Neuronen und reduzierte das Infarktvolumen im Vergleich zu Vehikel-behandelten 
MCAO-Ratten ganz beträchtlich. Unsere Befunde implizieren, dass die direkte Inhibierung 
der mtPTP durch Melatonin essentiell zum antiapoptotischen Effekt dieser Substanz bei 
transienter Hirnischämie beiträgt. 
Da oxidativer/nitrosativer Stress ein pathologischer Hauptfaktor in der apoptotischen 
Kaskade der cerebralen Ischämie ist, wurde weiteres natürlich vorkommendes 
Antioxidants, das Oxyresveratrol (OXY), untersucht in Bezug auf seinen potentiellen 
neuroprotektiven Effekt. Erneut kam dazu das MCAO-Modell transienter Hirnischämie 
zum Einsatz. OXY wurde wiederholt i. p. appliziert: einmal sofort nach Okklusion und 
einmal zum Zeitpunkt der Reperfusion. 10 bzw. 20 mg/kg OXY reduzierten das 
Hirninfarktvolumen im Vergleich zu Vehikel-behandelten MCAO-Ratten um mehr als die 
Hälfte (um 54 ± 4% bzw. 63 ± 5 %). Auch die neurologischen Defizite, die anhand 
verschiedener Verhaltensparameter erfasst wurden, waren in OXY-behandelten MCAO-
Ratten geringer ausgeprägt. Die histologische Analyse von Apoptose-Markern im 
ischämischen Hirnareal zeigte, dass OXY die cyt c-Freisetzung aus Mitochondrien und die 
nachfolgende Caspase-3-Aktivierung in MCAO-Ratten verringerte. Zudem reduzierte 
OXY die Anzahl der sich in Apoptose befindenden Zellen im ischämischen Hirnareal im 
Vergleich zu Vehikel-behandelten MCAO-Ratten, wie unter Verwendung von Antikörpern 
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gegen apoptotische Einzelstrang-DNA nachgewiesen werden konnte. Diese Befunde 
belegen in dem von uns verwendeten in-vivo-Schlaganfall-Modell, dass OXY nach akuter 
Hirnischämie zur Verringerung der Schädigung des Hirngewebes führt. 
Befunde, die in der Dissertation, wie auch in den daraus resultierenden Publikationen 
vorgestellt wurden, belegen, dass sowohl Melatonin als auch OXY, interessante 
Kandidaten für eine erfolgreiche Intervention in der Schlaganfall-Therapie sind.  
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8 .  L I S T  O F  A B B R E V I A T I O N S  
 
 
 
ADP Adenosine diphosphate 
AIF Apoptosis inducing factor 
AMP Adenosine monophosphate 
AMPA α-amino-3-hydroxy-5-methyl-4-isoxalone propionic acid 
ANT Adenine nucleotide translocase 
Apaf-1 Apoptotic protease-activating factor-1 
ATP Adenosine triphosphate 
BAX Bcl2 associated protein X 
BGlu Blood glucose 
CAD Caspase activated DNase 
CBF Cerebral blood flow 
CsA Cyclosporine A 
Cu\Zn SOD Copper \ zinc superoxide dismutase 
DMEM Dulbecco’s modified Eagle’s medium 
ER Endoplasmic reticulum 
F0 F1-ATP F0 F1-ATP synthase 
FCS Fetal calf serum 
H2O2 Hydrogen peroxide 
HBSS Hepes buffered salt solution 
Hct Hematocrit 
ICAD Inhibitor of caspase activated DNase 
MAP-2 Microtubule associated protein 2 
MABP Mean arterial blood pressure 
MCA Middle cerebral artery 
MCAO Middle cerebral artery occlusion 
MDR Multi drug resistance pump 
Mel Melatonin 
MeValCsA  N-methyl-valine-4-cyclosporine A  
Mn-SOD Manganese superoxide dismutase 
mtPTP Mitochondrial permeability transition pore 
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NeuN Neuronal nuclear protein 
NFkB Nuclear factor kappa B 
NO Nitric oxide 
NOS Nitric oxide synthase 
NMDA N-methyl-D-aspartate 
NMR Nuclear magnetic resonance 
OGD Oxygen-glucose deprivation 
.OH Hydroxyl radical 
O2.- Superoxide anion 
ONOO- Peroxynitrite 
OMM Outer mitochondrial membrane 
OXY Oxyresveratrol 
PARP Poly (ADP ribose) polymerase 
PBS Phosphate buffered saline 
PFA Para formaldehyde 
ROS Reactive oxygen species 
RNS Reactive nitrogen species 
SOD Superoxide dismutase 
SPMA Spontaneous motor activity 
ssDNA Single stranded DNA 
VDAC Voltage-dependent anionic channel 
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